LRRC15 suppresses SARS-CoV-2 infection and controls collagen production

Lipin Loo

University of Sydney

Matthew Waller

University of Sydney

Alexander Cole

Centenary Institute and Faculty of Medicine and Health,

Alberto Stella

Kirby Institute UNSW

Cesar Moreno

Charles Perkins Centre, Centenary Institute

Christopher Denes

Charles Perkins Centre, Centenary Institute <https://orcid.org/0000-0002-8669-8088>

Zina Hamoudi

Charles Perkins Centre, Centenary Institute

Felicity Chung

Charles Perkins Centre, Centenary Institute

Anupriya Aggarwal

UNSW Sydney

Jason Low

The University of Sydney <https://orcid.org/0000-0003-0862-0012>

Karishma Patel

The University of Sydney <https://orcid.org/0000-0003-3034-3840>

Rezwan Siddiquee

The University of Sydney

Joel Mackay

University of Sydney <https://orcid.org/0000-0001-7508-8033>

Stuart Turville

UNSW Sydney <https://orcid.org/0000-0003-1918-5343>

Daniel Hesselton

<https://orcid.org/0000-0002-8675-9426>

G. Neely (✉ greg.neely@sydney.edu.au)

University of Sydney

Article

Keywords: LRRC15, SARS-CoV-2, COVID-19, Spike, CRISPR activation screen, gain of function, long haul COVID-19

Posted Date: January 6th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1172665/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

TITLE: LRRC15 suppresses SARS-CoV-2 infection and controls collagen production

Authors

Lipin Loo^{1,5}, Matthew A. Waller^{1,5}, Alexander J. Cole², Alberto Ospina Stella³, Cesar L. Moreno¹, Christopher E. Denes¹, Zina Hamoudi¹, Felicity Chung¹, Anupriya Aggarwal³, Jason K. K. Low⁴, Karishma Patel⁴, Rezwan Siddiquee⁴, Joel P. Mackay⁴, Stuart Turville³, Daniel Hesselson², G. Gregory Neely^{1,6}

Affiliations

¹Charles Perkins Centre, Dr. John and Anne Chong Lab for Functional Genomics, Centenary Institute, and School of Life and Environmental Sciences, University of Sydney, Camperdown, NSW, Australia.

²Centenary Institute and Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, 2006, Australia

³The Kirby Institute, University of New South Wales, New South Wales, Australia.

⁴School of Life and Environmental Sciences, The University of Sydney, Sydney, New South Wales 2006, Australia.

⁵These authors contributed equally

⁶Lead contact

*Correspondence: greg.neely@sydney.edu.au (G.G.N.)

Abstract

Although ACE2 is the primary receptor for SARS-CoV-2 infection, a systematic assessment of factors controlling SARS-CoV-2 host interactions has not been described. Here we used whole genome CRISPR activation to identify host factors controlling SARS-CoV-2 Spike binding. The top hit was a Toll-like receptor-related cell surface receptor called *leucine-rich repeat-containing protein 15 (LRRC15)*. *LRRC15* expression was sufficient to promote SARS-CoV-2 Spike binding where it forms a cell surface complex with LRRC15 but does not support infection. Instead, LRRC15 functioned as a negative receptor suppressing both pseudotyped and live SARS-CoV-2 infection. *LRRC15* is expressed in collagen-producing lung myofibroblasts where it can sequester virus and reduce infection in *trans*. Mechanistically LRRC15 is regulated by TGF- β , where moderate LRRC15 expression drives collagen production but high levels suppress it, revealing a novel lung fibrosis feedback circuit. Overall, LRRC15 is a master regulator of SARS-CoV-2, suppressing infection and controlling collagen production associated with “long-haul” COVID-19.

Keywords

LRRC15, SARS-CoV-2, COVID-19, Spike, CRISPR activation screen, gain of function, long-haul COVID-19

Introduction

The Coronavirus 2019 (COVID-19) pandemic, caused by SARS-CoV-2, represents the greatest public health challenge of our time. As of November 2021, there have been over 250,000,000

reported cases of COVID-19 globally and in excess of 5,000,000 subsequent deaths (WHO). SARS-CoV-2 shows high sequence similarity (79.6%) with severe acute respiratory syndrome coronavirus (SARS-CoV-1), and because of this similarity, angiotensin-converting enzyme 2 (ACE2), the primary entry receptor for SARS-CoV-1, was quickly identified as the SARS-CoV-2 Spike receptor (Kuba et al., 2005; Li et al., 2003; Lu et al., 2020; Zhou et al., 2020). However, a comprehensive search for other host factors that promote SARS-CoV-2 Spike binding has not yet been reported.

To identify novel host factors that can influence cellular interactions with the SARS-CoV-2 Spike protein, we used a whole genome CRISPR activation approach. Using the Calabrese Human CRISPR Activation Pooled Library (Sanson et al., 2018), we identified a TLR-related cell surface receptor named leucine-rich repeat-containing protein 15 (LRRC15) as a novel SARS-CoV-2 Spike binding protein in three independent whole genome screens. LRRC15 was confirmed to promote Spike binding via flow cytometry, immunoprecipitation and confocal microscopy. Mechanistically, LRRC15 is not a SARS-CoV-2 entry receptor, instead ectopic LRRC15 expression was sufficient to inhibit SARS-CoV-2 pseudovirus infection and can also suppress live SARS-CoV-2 infection. *LRRC15* is primarily expressed in innate immune barriers including placenta, skin, and lymphatic tissues as well as perturbed-state tissue fibroblasts. By analysing single cell sequencing data from COVID lung infections, we found fibroblast numbers significantly increase, and collagen-producing fibroblasts are primarily LRRC15⁺. Importantly, LRRC15 expression can suppress SARS-CoV-2 pseudovirus infection in *trans* and its expression levels control collagen production in fibroblasts. Overall, we show LRRC15 is a master regulator

of SARS-CoV-2 infection outcomes, physically linking SARS-CoV-2 to perturbed-state fibroblasts, collagen production and fibrosis associated with “long-haul” COVID.

Results

High throughput SARS-CoV-2 Spike binding assay

Based on *a priori* knowledge of SARS-CoV-1, ACE2 was rapidly identified as the primary receptor for SARS-CoV-2 Spike protein (Zhou et al., 2020). To investigate other host factors that modulate cellular interactions with SARS-CoV-2 Spike, we employed a pooled CRISPR activation (CRISPRa) screening approach. To this end, we developed a novel cellular flow cytometry-based SARS-CoV-2 Spike binding assay using Alexa Fluor 488-labeled Spike protein (Spike488; **Figure 1A**). While wild-type HEK293T (WT HEK293T) cells that express low levels of ACE2 show minimal binding to Spike488, when we provided *ACE2* cDNA HEK293T-ACE2 cells exhibited high Spike488 binding activity (**Figure 1B**). To assess the sensitivity of this assay, we mixed HEK293T-ACE2 and WT HEK293T cells at various ratios and then measured Spike488 binding by flow cytometry. An increase in Spike488-binding cells could be detected when as little as 1% of the total population was ACE2⁺, indicating that this assay has sufficient sensitivity to enable genome-wide screens (**Figure 1C**). To perform a pooled CRISPRa screen with this system, we generated a stable HEK293T cell line expressing CRISPRa machinery (MS2-p65-HSF + VP64; HEK293T-CRISPRa) (**Figure 1D**). We tested HEK293T-CRISPRa clones for the ability to induce *ACE2* expression using 3 independent single guide RNAs (sgRNAs) (Horlbeck et al., 2016). We selected Clone 1 for further use, since it induced similar levels of *ACE2* expression compared to

cDNA overexpression, (**Supplementary Figure 1A**), and confirmed that CRISPRa induction of ACE2 expression conferred Spike488 binding by flow cytometry (**Figure 1E**).

CRISPR activation screening for regulators of SARS-CoV-2 Spike binding identifies LRRC15

Having established the utility of our system, we used the Calabrese Human CRISPR Activation Pooled guide Library (Sanson et al., 2018) to drive CRISPRa-dependent expression of the human genome in HEK293T-CRISPRa cells. Cells were infected with lentivirus-packaged CRISPRa sgRNAs and then selected on puromycin to enrich for transduced cells. Transduced cells were incubated with Spike488 and sorted by FACS to isolate CRISPRa-sgRNA cells with enhanced Spike binding. Overall, pooled CRISPRa-sgRNA cells showed more Spike binding than mock-transduced controls (**Supplementary Figure 1C**). Genomic DNA (gDNA) was collected from unselected or Spike488-selected cells and sgRNA abundance quantified by sequencing (**Figure 2A**) and then data analyzed using the MAGeCK analysis platform (v0.5.9) (Li et al., 2014) and plotted using MAGeCKFlute (v1.12.0) (Wang et al., 2019). Using an FDR cut off of 0.25, our top hit was the transmembrane protein LRRC15 (LogFC 4.748, P value 2.62×10^{-7} , FDR 0.00495), followed by the SARS-CoV-2 entry receptor ACE2 (LogFC 2.1343, P value 2.65×10^{-5} , FDR 0.25). (**Figure 2B-D; Supplementary Table 1**). Moreover, we conducted 2 additional screens under slightly different conditions, and in all screens our top hit was LRRC15 (**Supplementary Figure 2A-F**).

We expressed the *LRRC15* sgRNAs that were hits in our screens in HEK293T-CRISPRa cells and confirmed that they induce expression of *LRRC15* (~approximately 2000 fold induction,

Supplementary Figure 2G). Moreover, LRRC15-overexpressing cells dramatically increased SARS-CoV-2 Spike488 binding, with *LRRC15* sgRNA 1 inducing binding to levels comparable to cells overexpressing *ACE2* sgRNA3 (**Figure 2E**). LRRC15 overexpression did not itself upregulate *ACE2* transcription, suggesting the increased Spike binding in LRRC15-expressing cells is independent of *ACE2* upregulation (**Supplementary Figure 2H**). Conversely, only one of the three *ACE2* sgRNAs from the Calabrese library efficiently activated *ACE2* expression (**Supplementary Figure 2I-J**), explaining why *ACE2* itself was not a higher ranked hit in our 3 CRISPRa screens (**Figure 2D, Supplementary Figure 2A-F**). To avoid spectral overlap with GFP-expressing cell lines we conjugated Spike with Alexa Fluor 647 (Spike647), which was used for the rest of the study. Using *ACE2* sgRNA3 and *LRRC15* sgRNA1 cells, we measured 11.6 nM affinity for ACE2/Spike647, which is similar to previous estimates (range: 4.7 - 133.3 nM (Lan et al., 2020; Wang et al., 2020; Wrapp et al., 2020)) and 68.8 nM for LRRC15/Spike647 (**Figure 2F**).

LRRC15 is a new transmembrane SARS-CoV-2 Spike interacting protein

LRRC15 is a 581 amino acid (a.a.) leucine-rich repeat (LRR) protein with 15 extracellular LRRs followed by a single transmembrane domain and a short 22 a.a. intracellular domain (**Figure 3A and 3B**). LRRC15 belongs to the LRR Tollkin subfamily that includes TLR1-13 and is most closely related to the platelet von Willebrand factor receptor subunit Glycoprotein V (GP5) (Dolan et al., 2007) (**Figure 3C**, full tree in **Supplementary Figure 3A**). To confirm a role for LRRC15 in SARS-CoV-2 Spike binding and ensure the interaction was not an artifact of our CRISPRa strategy, we transfected *LRRC15*-GFP cDNA into HEK293T cells and observed Spike647 binding

by flow cytometry. There are two reported isoforms of LRRC15 (LRRC15_1 and LRRC15_2), with LRRC15_1 having 6 additional amino acids at the N-terminus. Although cells transfected with GFP alone showed no binding to Spike647, cells expressing *LRRC15* isoform 1 or 2 both showed strong Spike binding (**Figure 3D**). While LRRC15-dependent Spike binding was higher than cells stably expressing ACE2 (62.1% and 64.5% vs. 48.8%), co-expression of LRRC15 with ACE2 was additive resulting in 86.3% positive (LRRC15_1) or 83.8% positive (LRRC15_2) cells (**Figure 3E**). Interestingly, all cells (100%) stably expressing ACE2 and TMPRSS2 bound Spike647 regardless of LRRC15 expression (**Figure 3F**). However, LRRC15 expression in HEK293T-*ACE2-TMPRSS2* cells still enhanced the amount of cell surface Spike647 bound by each cell as measured by mean fluorescence intensity (**Figure 3G**). Moreover, both *LRRC15* isoforms colocalized with Spike647 (**Figure 3H**). To independently confirm an interaction between LRRC15 and SARS-CoV-2 Spike protein, we added Spike to LRRC15-expressing cells and then immunoprecipitated LRRC15. While control GFP transfected HEK293T cells did not show any signal at the size predicted for Spike (~200 kDa, (Hsieh et al., 2020)) (**Supplementary Figure 3B-C**), when we expressed and then pulled down either LRRC15_1 or LRRC15_2, in both cases we co-immunoprecipitated Spike protein in the eluate (**Figure 3I**). Taken together, these data show that LRRC15 expression is sufficient to confer SARS-CoV-2 Spike binding to HEK293T cells, and LRRC15 can further enhance Spike interactions in the presence of ACE2 and TMPRSS2.

LRRC15 is not a SARS-CoV-2 entry receptor but can suppress Spike-mediated entry and live virus infection

We next asked if LRRC15 can act as a receptor for SARS-CoV-2 and mediate viral entry. For this we used a SARS-CoV-2 pseudotyped lentivirus system (SARS-CoV-2 pseudovirus) that displays the SARS-CoV-2 Spike protein and carries a luciferase reporter (**Figure 4A, Supplementary Figure 4A**). Surprisingly, LRRC15 did not confer SARS-CoV-2 pseudovirus tropism in minimally infectable HEK293T cells (**Figure 4B**). We then tested if LRRC15 expression impacted infection of HEK293T cells expressing ACE2 and TMPRSS2 (**Figure 4C**, HEK293T-*ACE2* cells shown in **Supplementary Figure 4B-C**), which are highly sensitive to live SARS-CoV-2 infection. Indeed, compared to transfected controls, LRRC15-expressing HEK293T-*ACE2-TMPRSS2* cells show a strong ability to suppress SARS-CoV-2 pseudovirus infection, ranging from 56% suppression of infection at the lowest viral dose (2×10^6 particles) to 24% suppression at the highest viral dose (5×10^8 particles) (**Figure 4C**). Next we tested if LRRC15 expression can also suppress viral replication and cytopathic effect in a live SARS-CoV-2 infection system. HEK293T-*ACE2-TMPRSS2* cells were infected with increasing doses of SARS-CoV-2 (D614G and Delta variants, **Figure 4D**) and cell death was assessed 48 h later. Ectopic expression of LRRC15 significantly inhibited D614G infection (two-way ANOVA, $p < 0.05$) but not the Delta variant (**Figure 4E and 4F**). Together, these data show that LRRC15 is not sufficient to confer SARS-CoV-2 tropism and instead can act to reduce SARS-CoV-2 infection.

LRRC15 is found on lung fibroblasts that are not infected by SARS-CoV-2

At the tissue level, *LRRC15* RNA is most abundant in the placenta, with expression also found in skin, tongue, tonsils, and lung (Uhlén et al., 2015). At the single cell level, we used the COVID-19 Cell Atlas data set to confirm *LRRC15* expression in placenta decidua stromal cells (Vento-

181 Tormo et al., 2018), multiple lymphatic vessels (Huang et al., 2021; Madissoon et al., 2019; Martin
182 et al., 2019; Park et al., 2020), and fibroblasts from the skin (Solé-Boldo et al., 2020), prostate
183 (Henry et al., 2018) and lung (Bharat et al., 2020; Buechler et al., 2021; Delorey et al., 2021;
184 Madissoon et al., 2019; Melms et al., 2021; Vieira Braga et al., 2019) (**Figure 5A**). In the lung
185 (Melms et al., 2021) (**Figure 5B**) we found *LRRC15* is primarily expressed in fibroblasts as well
186 as a population annotated as “neuronal cells” (**Figure 5C**), and these populations were not infected
187 with SARS-CoV-2 (**Figure 5D**). These data were corroborated by two other COVID-19 patient
188 single cell/nucleus RNAseq data sets that show similar *LRRC15* fibroblast expression profiles
189 (**Supplementary Figure 5A-F**), which were also not infected (Delorey et al., 2021)
190 (**Supplementary Figure 5C**). Together, these data support our *in vitro* observations that *LRRC15*
191 does not mediate SARS-CoV-2 infection but may instead act as an innate immune barrier. In
192 contrast, ACE2 was detected primarily in uninfected type I (AT1) and (AT2) alveolar epithelium
193 (**Figure 5D**), and SARS-CoV-2-infected alveolar epithelium (“Other epithelial cells”) that lost
194 AT1/2 markers and upregulated ribosomal transcripts consistent with viral infection and cell death.
195

196 As single cell data showed an absence of SARS-CoV-2 mRNA in *LRRC15*⁺ fibroblasts, we next
197 tested infectivity of lung fibroblasts (IMR90) with SARS-CoV-2 pseudovirus. IMR90 fibroblasts
198 express *LRRC15* endogenously (**Supplementary Figure 5G**) and possess a low level of intrinsic
199 SARS-CoV-2 Spike binding activity (**Supplementary Figure 5H**). Endogenous *LRRC15*
200 expression was confirmed via Western blot (**Supplementary Figure 6A-B**). Transfection of
201 *LRRC15*-GFP cDNA in these fibroblasts further enhanced Spike binding capacity (**Figure 5E**).
202 However, similar to WT HEK293T cells, ectopic expression of *LRRC15* was not sufficient to
203 confer SARS-CoV-2 pseudovirus tropism (**Figure 5F**), confirming that *LRRC15* is not a SARS-

CoV-2 entry receptor. Since *LRRC15* and *ACE2* expression are mutually exclusive in the lung, we next investigated whether *LRRC15*⁺ fibroblasts could act in *trans* to sequester SARS-CoV-2 pseudovirus and suppress infection of the highly permissive HEK293T-*ACE2-TMPRSS2* line. Indeed, co-incubating permissive HEK293T-*ACE2-TMPRSS2* cells with *LRRC15*⁺ fibroblasts could suppress SARS-CoV-2 pseudovirus transduction (**Figure 5G**). Thus, *LRRC15* is expressed on lung fibroblasts where it can bind SARS-CoV-2 spike and help sequester virus from *ACE2*-expressing SARS-CoV-2 target cells.

LRRC15 is a key regulator of collagen expression

Pulmonary fibrosis, driven by fibroblasts, is a hallmark of COVID-19, especially in patients with “long-haul” disease (George et al., 2020; Rendeiro et al., 2021). To explore the drivers of fibrosis, we examined single cell datasets from the lungs of control vs COVID-19 patients (Bharat et al., 2020; Delorey et al., 2021; Melms et al., 2021), and found a significant increase in the proportion of fibroblasts in COVID-19 lungs (7.9% in control and 22.9% in COVID-19 patients, **Figure 6A**). A recent study on the organization of tissue fibroblasts identified *LRRC15* as a lineage marker for perturbed state activated myofibroblasts (Buechler et al., 2021). These specialized fibroblasts arise during disease, express collagen and other ECM-modifying genes, and participate in tissue repair and fibrosis (Buechler et al., 2021). We also observed lung *LRRC15*⁺ myofibroblasts in multiple COVID-19 patient data sets, and these cells express collagen (**Figure 6B**). *LRRC15* is upregulated in response to proinflammatory cytokines like IL1 β , IL6, and TNF α (Satoh et al., 2002), and TGF β also upregulates *LRRC15* (**Figure 6C**) and *COL1A1* transcripts (**Figure 6D**). Together, *LRRC15*

is expressed on collagen producing fibroblasts both *in vitro* and in the lung of COVID-19 patients and may regulate lung fibrosis.

To directly investigate the relationship between LRRC15 and collagen, we expressed low (Lo) or high (Hi) levels of LRRC15 in fibroblasts (or provided GFP as a transfection control) and then evaluated *COL1A1* expression (**Figure 6E**). Surprisingly, *Lo LRRC15* promoted *COL1A1* expression while *Hi LRRC15* did not (**Figure 6F**). This bimodal regulation was confirmed with Western blotting (**Figure 6G**, quantified in **H-I**, full blots in **Supplementary Figure 6**). When taken together, our working model is that LRRC15 expression is induced by inflammatory cytokines in COVID-19 lung fibroblasts, where it acts as an innate antiviral barrier that can sequester SARS-CoV-2 and decrease infection. As infection resolves, and the proinflammatory context of the lung changes, LRRC15 expression would reduce, and this would then switch LRRC15⁺ fibroblasts from antiviral role to instead promote lung repair (**Figure 6J**). Overall, we describe the TLR-related receptor LRRC15 as a master regulator of SARS-CoV-2 infection, with the ability to gauge lung context and physically suppress SARS-CoV-2 infection or promote lung repair. We propose that dysregulation of this novel feedback system may play a role in the intense lung fibrosis observed in “long-haul” COVID-19 patients.

Discussion

Using an unbiased functional genomics approach, we have identified the leucine rich repeat receptor, LRRC15 as a master regulator of SARS-CoV-2 infection and lung repair. LRRC15

promotes SARS-CoV-2 spike binding comparable to ACE2, however this receptor is not sufficient to confer viral tropism. LRRC15 is normally highly expressed in the placenta, skin, and various lymphatics, and is related to TLR innate immune receptors. In previous work, LRRC15 has been shown to suppress adenovirus infection (O'Prey et al., 2008), and here we show LRRC15 can also suppress SARS-CoV-2 Spike pseudovirus and live SARS-CoV-2 infection. Given the expression pattern and function of LRRC15, we hypothesize that this molecule may comprise a new cellular innate immune barrier that is critical for host defense. Importantly, LRRC15 is found on collagen-producing myofibroblasts where it regulates collagen production, directly linking SARS-CoV-2 with the development of lung fibrosis seen in "long-haul" COVID-19.

LRRC15 was initially identified as a factor induced by pro-inflammatory cytokines that would be present in the lungs of COVID-19 patients (Satoh et al., 2002). LRRC15 is a member of the LRR superfamily and LRR-Tollkin subfamily of LRR-containing proteins, many of which play critical roles in host defense (Dolan et al., 2007). Of the TLR family, LRRC15 is most related to TLR5, which also recognises a major extracellular virulence factor, the bacterial extracellular protein flagellin (Hayashi et al., 2001). Remarkably, while this manuscript was in preparation, Shilts et al. released a preprint describing a similar CRISPR activation strategy to identify new host factors that can regulate Spike binding; their screen also pulled out LRRC15 as a top factor driving Spike/host cell interactions (Shilts et al., 2021). This study corroborates our findings, despite their use of different Spike formulations, CRISPRa machinery, and cell lines. Together, these studies highlight a fundamental new role for LRRC15 in SARS-CoV-2 biology.

Several CRISPR Loss of Function (LOF) and Gain of Function (GOF) screens have been reported in attempts to identify novel SARS-CoV-2 interactors and regulators. Though these CRISPR screens have been successful in identifying novel SARS-CoV-2 receptors and co-receptors (Baggen et al., 2021; Goujon et al., 2021; Schneider et al., 2021; Wang et al., 2021; Zhu et al., 2021), ACE2-regulators (Daniloski et al., 2021; Wei et al., 2021), complexes such as the vacuolar ATPase proton pump, Retromer, Commander and SWI/SNF chromatin remodeling machinery (Daniloski et al., 2021; Wei et al., 2021) implicating many new pathways in SARS-CoV-2 infection (Daniloski et al., 2021; Schneider et al., 2021; Wang et al., 2021), they have all failed to identify LRRC15. This difference is likely due to SARS-CoV-2 live virus and pseudovirus screens being unable to divorce Spike binding from downstream effects of infection. Our fluorophore-conjugated Spike protein/pooled CRISPR screening model thus represents a new paradigm for investigating host/virus interactions independent of virion entry or cell death.

Although our data shows that LRRC15 promotes cellular binding to SARS-CoV-2 Spike protein, we also show that LRRC15 does not act as an entry receptor, but instead inhibits SARS-CoV-2 pseudotyped lentivirus infection. This observation is consistent with a report that LRRC15 can also impede adenovirus infection (O'Prey et al., 2008). When we tested live SARS-CoV-2 strains we also observed a significant anti-SARS-CoV-2 activity for LRRC15, although LRRC15 was much more effective against the D614G vs. the Delta variant. We hypothesize that LRRC15 may play a role in limiting SARS-CoV-2 transmission by sequestering free virus in the airways of COVID-19 patients, and the Delta variant has adapted to reduce this effect allowing for higher transmission.

While our data highlights a new role for LRRC15 in promoting SARS-CoV-2 Spike binding, limiting infection, and regulating collagen expression, it is currently unclear how LRRC15 contributes to human COVID-19 disease. We consider multiple possible mechanisms. *In vivo*, LRRC15 may provide an innate barrier that can slow infection or limit transmission, allowing additional innate mechanisms to clear SARS-CoV-2. For example, LRRC15 could mediate a Tetherin-like function to anchor exiting viral particles to limit spread of the virus through the tissue (Neil et al., 2008). Since in the lung *LRRC15* is found in *ACE2* negative cells, LRRC15 could primarily act to physically sequester SARS-CoV-2 virions away from permissive cells. Alternatively, the level of LRRC15 expression could control how lung or other tissue fibroblasts react to infection. We found LRRC15 is regulated by TGF β , and others have reported LRRC15 is upregulated by proinflammatory cytokines including TNF α , IL-1 β and IFN γ (Sato et al., 2002). Thus, under conditions of appropriate inflammation, LRRC15 may be upregulated and play a primary role in immobilizing and sequestering viral particles to control infection while also suppressing lung fibrosis. LRRC15 may even help fibroblasts pass immobilized virus to innate lung antigen presenting cells, and a recently published spatial-resolution single cell analysis of the lung in COVID-19 showed that lung fibroblasts interact with SARS-CoV-2 Spike+ macrophages and dendritic cells (Rendeiro et al., 2021). Then when inflammation subsides, LRRC15 levels decrease, and lower levels of LRRC15 then promote collagen deposition supporting lung repair. When this system is dysregulated, for example in conditions of chronic lung infection, LRRC15 levels may drop during infection, with inappropriate collagen production then leading to “long-haul” COVID.

Our unbiased functional genomic investigation of SARS-CoV-2 Spike/host interactions identified the novel TLR-related receptor LRRC15 as a powerful host factor driving SARS-CoV-2 Spike interactions. Further investigation into how LRRC15 contributes to SARS-CoV-2 pathology will help us better understand and treat this and future pandemics.

Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Graham G. Neely (greg.neely@sydney.edu.au).

Materials availability

This study did not generate any new unique reagents.

Data and code availability

CRISPR screen raw read counts have been deposited at GSE186475 and are publicly available as of the date of publication. CRISPR screen analysis is shown in **Figure 2** and **Supplementary Figure S2**. CRISPR screen output is deposited in **Supplementary Table S1**. This paper also analyzes existing publicly available single cell RNA-sequencing data. The accession numbers for these datasets are listed in the Key Resources Table. All data reported in this paper will be shared by the lead contact upon request. This paper does not report original code. Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

Experimental model and subject details

339

340 **Cell culture**

341 HEK293T cells (female; ATCC, CRL-3216, RRID: CVCL_0063) were cultured in Dulbecco's
342 Modified Eagle Medium (ThermoFisher Scientific, Cat #11995065) with 10% HyClone Fetal
343 Bovine Serum (Cytiva, SH30084.03) and 1% Penicillin-Streptomycin (Gibco, 15140122) at 37°C,
344 5% CO₂ and atmospheric oxygen. IMR90 E6E7 (female) cells were a gift from Anthony Cesare
345 (Children's Medical Research Institute, Sydney, Australia). IMR90 E6E7 were cultured in DMEM
346 (ThermoFisher Scientific, 11995065) supplemented with 10% HyClone FBS (Cytiva,
347 SH30084.03) and 1x non-essential amino acids (Gibco, 11140050) at 37°C, 3% O₂ and 10% CO₂.
348 Expi293FTM cells (female; ThermoFisher Scientific, A14527, RRID:CVCL_D615) were cultured
349 in Expi293TM Expression Medium (ThermoFisher Scientific, A1435101) with 5% CO₂ and
350 atmospheric O₂ at 37 °C for 24 h and then lowered to 32 °C for 72 h. Cell lines have been
351 authenticated.

352

353 **Method Details**

354

355 **Generation of CRISPR activation cell line**

356 HEK293T cells were co-transfected with pPB-
357 R1R2_EF1aVP64dCas9VP64_T2A_MS2p65HSF1-IRESbsdpa (Addgene #113341) and the
358 Super PiggyBac Transposase Expression Vector (System Biosciences, PB210PA-1) using
359 Lipofectamine 3000 Transfection Reagent (ThermoFisher Scientific). These cells (HEK293T-
360 CRISPRa) were then selected on blasticidin (Merck) at 5 µg/mL for 10 days prior to clonal
361 isolation and expansion.

362

363 **sgRNA vector cloning**

364 Single guide RNA (sgRNA) sequences for non-targeting control and ACE2 were taken from the
365 Weissman Human Genome-wide CRISPRa-v2 library (Addgene #83978). LRRC15 sgRNA
366 sequences and additional ACE2 sgRNA sequences were taken from the Human CRISPR activation
367 pooled library set A (Addgene #92379). Sense and antisense strands for each sequence were
368 ordered as DNA oligonucleotides (IDT) with 5' overhangs of 5'-CACC-3' on the sense strand
369 oligonucleotide and 5'-AAAC-3' on the antisense strand oligonucleotide. Oligonucleotides were
370 annealed at 4°C for 16 h and pXPR-502 (Addgene #96923) was digested with Esp3I
371 (ThermoFisher Scientific, ER0451) or BsmBI-v2 (New England Biolabs). sgRNA DNA
372 oligonucleotide duplexes were ligated into the digested pXPR-502 backbone using T4 ligase (New
373 England Biolabs) and incubated at 4°C overnight. NEB 10-beta competent *E. coli* (New England
374 Biolabs) were transformed with 100 ng of each sgRNA construct by heat-shock, plated onto LB-
375 agar plates (Life Technologies) containing ampicillin (Sigma-Aldrich) and grown at 37°C.
376 Individual colonies were picked, expanded in Luria broth (Life Technologies) supplemented with
377 ampicillin and amplified constructs were harvested using either ISOLATE II Plasmid Mini Kit
378 (Bioline) or PureYield Plasmid Maxiprep System (Promega Corporation).

379

380 **Whole genome sgRNA library amplification**

381 MegaX DH10B T1^R ElectrocompTM Cells (ThermoFisher Scientific) were electroporated with 400
382 ng Human CRISPR activation pooled library set A (Addgene #92379) and left to recover in
383 Recovery Medium for 1 hour at 37°C. Cells were then spread on 600 cm² LB-agar plates
384 supplemented with carbenicillin (Merck) and incubated at 37°C for 16 hours. All colonies were

scraped, collected and processed using the PureYield Plasmid Maxiprep System (Promega Corporation). The concentration of the plasmid library was determined via Nanodrop (ThermoFisher Scientific).

Lentivirus production and viral transduction

Lipofectamine 3000 Transfection Reagent (ThermoFisher Scientific) in Opti-MEM Medium (Gibco) was used to co-transfect HEK293T cells with psPAX2 (Addgene #12260), pCAG-VSVg (Addgene #35616) and either individual sgRNA constructs ligated into pXPR-502 (Addgene #96923) or pooled CRISPRa library (Human CRISPR activation pooled library set A, Addgene #92379) according to the manufacturer's instructions. Cells were incubated with transfection reagents for 16 h before the media was replaced. Viral media was collected 24 h later. For individual sgRNA constructs, neat viral media was added to HEK293T-CRISPRa cells with Polybrene Infection / Transfection Reagent (Sigma-Aldrich) at a concentration of 8 µg/mL. Viral media was replaced with fresh medium the following day and puromycin dihydrochloride (Gibco) added 24 h later at a concentration of 1.6 µg/mL for 72 h selection. For sgRNA library virus, viral media was passed through a 0.45 µm filter (Merck Millipore) and concentrated using 100K MWCO Pierce Protein Concentrators (Life Technologies Australia). Concentrated virus was then stored at -80°C.

SARS-CoV-2 Spike protein production

The expression construct for recombinant soluble trimeric SARS-CoV-2 spike protein (residues 1-1208, complete ectodomain) was generously provided by Dr Florian Krammer (Icahn School of Medicine, Mt Sinai). This protein was used for the initial setup of the screen (shown in Figure 1)

and in one CRISPRa screen (Screen 2). This construct includes the SARS-CoV-2 spike native signal peptide (residues 1-14) to target the recombinant protein for secretion, stabilising proline substitutions at residues 986 and 987, substitution of the furin cleavage site (residues 682-685) with an inert GSAS sequence, and a C-terminal His6-tag to enable affinity purification.

Soluble trimeric SARS-CoV-2 spike was expressed in EXPI293F™ cells via transient transfection using 25 kDa linear polyethyleneimine (PEI) (Polysciences Inc.). EXPI293F™ cultures were grown at 37°C, with shaking at 130 rpm, to a cell density of 3×10^6 cells/mL before transfection with pre-formed SARS-CoV-2 spike plasmid DNA:PEI complexes (2 µg/mL DNA and 8 µg/mL PEI). The transfected cells were incubated at 37°C for 24 h and then at 32°C for a further 72 h before harvesting. Culture medium, containing secreted SARS-CoV-2 spike, was harvested by centrifugation at 4000 g for 20 min. Supernatants from the centrifugation step were supplemented with 20 mM HEPES (pH 8.0) and subjected to immobilised metal affinity chromatography (IMAC) by incubation with Ni-NTA agarose pre-equilibrated with a buffer consisting of 20 mM NaH_2PO_4 (pH 8.0), 500 mM NaCl, and 20 mM imidazole. His6-tagged SARS-CoV-2 spike protein was eluted from the Ni-NTA agarose using a buffer comprising 20 mM NaH_2PO_4 (pH 7.4), 300 mM NaCl, and 500 mM imidazole. Eluates from affinity chromatography were concentrated and further purified by gel filtration chromatography using a Superdex 200 10/30 GL column (Cytiva) and buffer consisting of 20 mM HEPES (pH 7.5) and 150 mM NaCl. The quality of protein purification was assessed by SDS-PAGE and multiple angle laser light scattering (MALLS).

The expression construct for a more stable variant of soluble trimeric SARS-CoV-2 spike ectodomain protein called “HexaPro” was a gift from Jason McLellan (Addgene, #154754). This

“Hexapro” protein was used in 2 CRISPRa screens (Screen 1 and 3) and in all validation experiments. This construct, in addition to above, includes 6 total stabilising proline substitutions at residues 817, 892, 899, 942, 986 and 987. The protein was expressed, and the culture medium was harvested as above. The supernatant containing the protein was supplemented with 20 mM HEPES pH 8.0 and subjected to IMAC with Ni-NTA as above. The eluate was dialysed to a buffer containing 2 mM Tris (pH 8.0) and 200 mM NaCl and concentrated to reduce the total volume by a factor of 3. The sample was passed through a 0.22 µm filter and purified by gel filtration chromatography using HiLoad 16/600 Superdex 200 (Cytiva) in a buffer composed of 2 mM Tris (pH 8.0) and 200 mM NaCl. The quality of the protein was assessed by SDS-PAGE and MALLS.

Conjugation of SARS-CoV-2 Spike glycoprotein with fluorophores

Spike protein was conjugated to Alexa FluorTM 488 or Alexa FluorTM 647 using protein labelling kits (Invitrogen) according to manufacturer’s instructions. Briefly, 50 µL of 1 M sodium bicarbonate was added to 500 µl of 2 mg/mL Spike protein. The solution was then added to room temperature Alexa FluorTM 488 or 647 reactive dye and stirred for 1 h at room temperature. Conjugated spike proteins were loaded onto Bio-Rad BioGel P-30 Fine size exclusion purification resin column and eluted via gravity (Alexa FluorTM 488) or centrifugation (Alexa FluorTM 647). NanoDrop (ThermoFisher Scientific) was used to determine protein concentration.

Generation of ACE2 and dual ACE2/TMPRSS2 cDNA overexpression cell lines

HEK293T cells stably expressing human ACE2 (HEK293T-*ACE2*) were generated by transducing HEK293T cells with a lentivirus expressing *ACE2* (Tea et al., 2021). Briefly, ACE2 ORF was cloned into a 3rd generation lentiviral expression vector, pRRLsinPPT.CMV.GFP.WPRE

(Follenzi et al., 2004) using AgeI/BsrGI cut sites, thus replacing *GFP ORF* with *ACE2* to create a novel expression plasmid, herein referred to as *ppt-ACE2*. Lentiviral particles expressing *ACE2* were produced by co-transfecting *ppt-ACE2*, a 2nd generation lentiviral packaging construct *psPAX2* and *VSV-G* plasmid *pMD2.G* (Addgene #12259) in HEK293T cells by using polyethylenimine as previously described (Aggarwal et al., 2012). Virus supernatant was harvested 72 hours post transfection, pre-cleared of cellular debris and centrifuged at 28,000 xg for 90 minutes at 4 °C to generate concentrated virus stocks. To transduce HEK293T cells, 10,000 cells per well were seeded in a 96 well tissue culture plate and virus supernatant added in a 2-fold dilution series. At 72 hours post transduction the surface expression of *ACE2* was measured by immunostaining the cells with anti-*ACE2* monoclonal antibody (Thermo Fisher Scientific, MA5-32307). Cells showing maximal expression of *ACE2* were then sorted into single cells using BD FACS Aria III cell sorter to generate clonal populations of HEK293T-*ACE2* cells.

For generating HEK293T cells expressing both *ACE2* and *TMPRSS2* (HEK293T-*ACE2-TMPRSS2*), HEK293T-*ACE2* cells described above were transduced with lentiviral particles expressing *TMPRSS2*. To achieve this, *hTMPRSS2a* (synthetic gene fragment; IDT) was cloned into lentiviral expression vector *pLVX-IRES-ZsGreen* (Clontech) using *EcoRI/XhoI* restriction sites and lentiviral particles expressing *TMPRSS2* were produced as described above. Lentiviral transductions were then performed on HEK293T-*ACE2* cells to generate HEK293T-*ACE2-TMPRSS2* cells. Clonal selection led to the identification of a highly permissive clone, HekAT24 (Tea et al., 2021), which was then used in subsequent experiments.

Optimizing a flow cytometry-based assay for determining SARS-CoV-2 Spike binding

HEK293T-*ACE2* cells were dissociated by incubating with TrypLE for 5 min at 37°C and neutralized with DMEM. 10⁶ cells were collected, washed with 1% bovine serum albumin (BSA; Sigma-Aldrich) in Dulbecco's Phosphate Buffered Saline (DPBS; Sigma-Aldrich) and then incubated with increasing concentrations of Alexa Fluor 488-conjugated SARS-CoV-2 spike glycoprotein (Spike488) for 30 min at 4°C. The cells were then washed once with DPBS before resuspending in 1% BSA in DPBS and analyzed using the Cytex Aurora (Cytex Biosciences). For cell mixing experiments, increasing proportions of HEK293T-*ACE2* cells (0%, 1%, 20%, 50%, 80% and 100%) were combined with decreasing proportions of wildtype (WT) HEK293T cells (100%, 99%, 80%, 50%, 20%, 0%) to a total of 10⁶ cells per sample. These samples were incubated with 50 µg/mL Spike488 as described above and analyzed using the Cytex Aurora (Cytex Biosciences).

To confirm the validity of this assay in detecting binding in cells expressing CRISPRa machinery, a clonal line of HEK293T with stable expression of a plasmid encoding dCas9-VP64 and SAM system helper proteins (pPB-R1R2_EF1aVP64dCas9VP64_T2A_MS2p65HSF1-IRESbsdpa) (HEK293T-CRISPRa) was transduced with lentivirus carrying *ACE2* sgRNA 1 or non-targeting control sgRNA. These cells were then incubated with Spike488 as previously described and analyzed on the Cytex Aurora (Cytex Biosciences).

CRISPR activation screening

HEK293T-CRISPRa cells were transduced with concentrated Human CRISPR activation pooled library set A (Addgene #92379)-carrying lentivirus at a multiplicity of infection (MOI) of approximately 0.5. Cells were selected on puromycin dihydrochloride (Gibco) at a concentration of 1.6 µg/mL for 3 days (screen 1 and 2). 3x10⁷ cells (>500 cells/guide) were incubated with

Spike488 for 30 min at 4°C, washed to remove excess spike protein, and sorted for increased Alexa Fluor 488 intensity using the BD FACSMelody Cell Sorter (BD Biosciences). Gates for flow assisted cytometric sorting were set using non-targeting control (NTC) sgRNA-transduced cells as a negative control and *ACE2* sgRNA-transduced cells as a positive control, both of which had been incubated with Spike488 under the same conditions as stated previously. Unsorted cells were maintained separately so as to be used as a diversity control. Cells were expanded and 2×10^6 cells were then collected for genomic DNA (gDNA) extraction for sorted samples and 3×10^7 for the unsorted diversity control. Remaining diversity control cells were re-seeded and once again incubated with Spike488 under the same conditions as stated previously (screen 3). These Spike-incubated cells were sorted again but selected on puromycin for eight days prior to expansion and collection of 1×10^7 cells from both the sorted cell population and the unsorted diversity control population for gDNA extraction. Gating strategy is shown in **Supplementary Figure 1B**.

gDNA was extracted from all collected cells using the ISOLATE II Genomic DNA Kit (Bioline). Samples were prepared for NGS via PCR. Genomic DNA (25 µg for unsorted diversity control samples, 5 µg for sorted samples) was added to NEBNext High-Fidelity 2X PCR Master Mix (New England Biolabs) and 0.4 µM P5 staggered primer mix and 0.4 µM of P7 indexing primer unique to each sample. PCR cycling conditions and primers were adapted from Sanson et al. (Sanson et al., 2018). Primer sequences can be found in **Supplementary Table S3**. Briefly, reactions were held at 95°C for 1 min, followed by 28 cycles of 94°C for 30 s, 53°C for 30 s and 72°C for 30 s, followed by a final 72°C extension step for 10 min. Amplicons were gel extracted and purified using the ISOLATE II PCR & Gel Kit (Bioline) and the quality and concentration of DNA assessed with the High Sensitivity DNA kit (Agilent Technologies). Samples were then sent to Novogene

for next generation sequencing. Raw next generation sequencing reads were then processed using MAGeCK (v0.5.9) (Li et al., 2014) to identify enriched genes. Plots were generated using MAGeCKFlute (v1.12.0) (Wang et al., 2019). Normalized read counts were produced using MAGeCK 'count' function on each pairing of unsorted diversity control and sorted sample. Mean and standard deviation was calculated for each individual sample (i.e. separately for diversity control and sorted sample) and the Z-score calculated using $Z = \frac{x - \mu}{\sigma}$, where x is the normalized read count for an individual sgRNA, μ is the mean of all normalized read counts in the sample and σ is the standard deviation of all normalized read counts in the sample.

Validation of ACE2 and LRRC15 by CRISPRa

To validate the function of LRRC15 in binding SARS-CoV-2 spike, clonal HEK293T-CRISPRa cells were transduced with lentivirus carrying *ACE2* sgRNAs, *LRRC15* sgRNAs or a NTC sgRNA. Cells were selected on 1.6 μ g/mL puromycin dihydrochloride (Gibco) for 3 days and then collected for analysis by RT-qPCR and flow cytometry. For validation by flow cytometry, 1×10^6 cells were incubated with 50 μ g/mL Spike647 as previously described and then analyzed using the Cytex Aurora (Cytex Biosciences). Binding affinity of ACE2 and LRRC15 were conducted with *ACE2* sgRNA3 and *LRRC15* sgRNA1 cells with 1, 5, 10, 25, 50 and 100 μ g/mL Spike647 (corresponding to 7, 35, 70, 175, 350 and 700 nM).

RNA extraction and RT-qPCR

RNA was isolated from cells using the ISOLATE II RNA Mini Kit (Bioline) and concentration was measured by Nanodrop (Thermo Scientific). cDNA was synthesized using the iScript Select cDNA Synthesis Kit (Bio-Rad) according to manufacturer's instructions. Briefly, 500 ng of RNA

was added to iScript RT Supermix and nuclease-free water to a final volume of 20 μ L. The assembled reactions were then incubated in a thermocycler as follows: 25°C for 5 min, 46°C for 20 min and then 95°C for 1 min. RT-qPCR was then performed on the cDNA samples using SYBR Select Master Mix (ThermoFisher Scientific) and the LightCycler 480 System (Roche). All primer sequences used are listed in the Key Resources Table. Results were analyzed using the $\Delta\Delta C_T$ method.

LRRC15 crystal structure prediction

The predicted crystal structure for LRRC15 was calculated using AlphaFold (v2.0) (Jumper et al., 2021) (<https://alphafold.ebi.ac.uk/entry/Q8TF66>) and sourced via UniProt (UniProt Consortium, 2021) (<https://www.uniprot.org/uniprot/Q8TF66>).

LRR Tollkin Phylogenetic Tree

Protein sequences of LRR Tollkin family members (Dolan et al., 2007) were clustered using Clustal Omega (v1.2.2) (Sievers et al., 2011). The phylogenetic (Newick) tree was visualized with MEGA11 (Sievers et al., 2011; Stecher et al., 2020).

Validation of LRRC15 independent of CRISPR activation

LRRC15-TurboGFP fusion constructs (Origene, RG225990 and RG221437) were used for flow cytometry, immunoprecipitation and immunocytochemistry experiments while *LRRC15-myc-DDK* fusion constructs (Origene, RC225990 and RC221437) were utilized for SARS-CoV-2 pseudovirus and SARS-CoV-2 live virus inhibition experiments. *LRRC15* transcripts were excised

from the *LRRC15-TurboGFP* and *LRRC15-myc-DDK* constructs and replaced with multiple cloning sites to generate empty vector controls for transfection.

To evaluate the role of LRRC15 in binding SARS-CoV-2 spike glycoprotein independent of CRISPR activation machinery, 2.5 µg of plasmids carrying the *GFP*-tagged *LRRC15* cDNA transcript 1 or 2, or empty vector control were transfected into HEK293T, HEK293T-*ACE2* and HEK293T-*ACE2-TMPRSS2* cells as described above. For each sample, 10⁶ cells were collected and incubated with Alexa Fluor 647-conjugated SARS-CoV-2 spike glycoprotein (Spike647) and analyzed using the Cytex Aurora (Cytex Biosciences) as described above.

Immunoprecipitation

For SARS-CoV-2 spike pulldown, 2x10⁷ HEK293T cells transfected with *LRRC15-TurboGFP* (transcript 1 and 2) or *pLJMI-EGFP* (Addgene #19319) were incubated with 50 µg/mL spike hexapropylamine for 30 min at 4°C with rotation. Cells were washed with DPBS (Sigma-Aldrich, D8537) and incubated for 15 min in lysis buffer (1% Igepal-CA-630, 5 mM Tris HCl (pH 7.4), 150 mM NaCl, 1 mM MgCl₂, 5% glycerol, 10 mM NaF, 10 mM sodium pyrophosphate, 10 mM sodium orthovanadate, 60 mM β-Glycerophosphate, 1X complete EDTA-free protease inhibitor (Roche)) on ice. Samples were then sonicated at 90% amplitude for 30 seconds using the BANDELIN SONOPULS mini20 and spun down at 18,000 g for 10 mins. Concentration of protein samples was determined using BCA assay (ThermoFisher Scientific). 1 µg of anti-LRRC15 antibody (Abcam, EPR8188(2)) or rabbit IgG (Covance, CTL-4112) was added to 1 mg protein lysate and incubated at 4°C with rotation for 2.5 h before precipitation with protein G (ThermoFisher Scientific). Immunoprecipitated proteins were eluted with 0.1 M Tris and 4% SDC. Input, flow-

through and eluate were mixed with 4X loading buffer and heated at 95°C for 5 min. Samples were loaded into pre-cast polyacrylamide gels (4-20% gradient, Bio-Rad) and electrophoresed at 90 V for 1.5 h. Proteins were transferred to 0.45 µm nitrocellulose membranes at 100 V for 1 h. Membranes were blocked in Intercept blocking buffer (LI-COR) for 30 min at room temperature with gentle agitation. Blocking solution was replaced with primary antibody (Spike, LRRC15) Intercept buffer and membranes incubated overnight at 4°C with gentle agitation. Membranes were washed three times with TBST for 5 min with agitation prior to the incubation of membranes with secondary antibody in Intercept buffer for 2 h at room temperature. Membranes were washed another three times with TBST and then imaged using the Odyssey CLx (LICOR).

Confocal imaging

13 mm round coverslips were coated with Matrigel (Corning) diluted in DPBS and incubated for 30 min at 37°C. HEK293T cells transfected with LRRC15 cDNA constructs were seeded onto the Matrigel-coated coverslips at a density of 50,000 cells per coverslip. The following day, cells were incubated with Alexa FluorTM 647-conjugated SARS-CoV-2 spike protein at a concentration of 10 µg/mL in culture media for 30 min at 37°C. The cells were fixed in 4% paraformaldehyde (PFA) for 20 min at room temperature, washed 3 times with DPBS. Cells were incubated with Hoechst (1:2000 in DPBS) for 20 minutes, washed 3 times and mounted onto Superfrost plus slides (Fisherbrand) and then imaged using the Leica TCS SP8 STED 3X at 40X magnification.

SARS-CoV-2 pseudotyped lentivirus production and neutralization assay

SARS-CoV-2 pseudovirus was produced using a five-component plasmid system. Plasmid encoding the SARS-CoV-2 spike protein with an 18 amino acid truncation of the C-terminus was

co-transfected into HEK293T cells with pBCKS(HIV-1SDmCMBeGFP-P2A-luc2pre-IIU), which permits equimolar expression of firefly luciferase and EGFP, and packaging plasmids pHCMVgagpolmlstwhv, pcDNA3.1tat101ml and pHCMVRevmlwhvpre. Transfection was carried out using Lipofectamine 3000 Transfection Reagent (ThermoScientific) according to manufacturer's instructions. 16 h after transfection, a media change was performed. Viral media was collected the following day, passed through a 0.45 μ m filter and then concentrated using 100K MWCO Pierce Protein Concentrators (Life Technologies Australia). Concentrated virus was then stored at -80°C. Pseudovirus particle concentrations were determined using the QuickTiter™ Lentivirus Titer Kit (Cell Biolabs, Inc) under manufacturer conditions.

For infection of cells with SARS-CoV-2 pseudovirus, *WT* HEK293T, HEK293T-*ACE2* and HEK293T-*ACE2-TMPRSS2* cells were transfected with cDNA for *myc-DDK*-tagged *LRRC15* transcript 1, empty *myc-DDK* construct as a control plasmid. Cells were seeded in 96-well plates, concentrated pseudovirus was added 24 hours later in the presence of 8 μ g/ml polybrene. Successful transduction of cells was confirmed by observing GFP expression 48 h post-transduction. The extent of transduction was quantified with the Steady-Glo Luciferase Assay System (Promega Corporation) according to the manufacturer's instructions. Briefly, plates were allowed to equilibrate to room temperature before 50 μ L of Steady-Glo reagent was added to each well containing 50 μ L of cell culture media. Plates were incubated at room temperature for 1 h to permit cell lysis and luminescence was then measured using a plate reader. Luminescence of the *LRRC15* cDNA- and control plasmid-transfected cells was normalized to luminescence values recorded in non-transduced wells for the corresponding cell type.

SARS-CoV-2 live virus infection assays

For assessing the inhibitory effect of native overexpression of *LRRC15*, HEK293T-*ACE2-TMPRSS2* cells were transfected with *myc-DDK*-tagged *LRRC15* transcript 1 plasmid (Origene, RC225990) for transient overexpression, with empty *myc-DDK* plasmid as a control plasmid. HEK293T-*ACE2-TMPRSS2* cells were seeded in 384-well plates at a density of 8×10^3 cells/well in the presence of NucBlue™ live nuclear dye (Invitrogen, USA) at a final concentration of 2.5% v/v. The SARS-CoV-2 isolates B.1.319 (“wildtype” D614G virus) and B.1.617.2 (Delta strain) were serially diluted in cell-culture medium and an equal volume was then added to the pre-plated and nuclear-stained cells to obtain the desired MOI doses. Viral dilutions were performed in duplicate. Plates were then incubated at 37°C for 48 hours before whole wells were imaged with an IN Cell Analyzer HS2500 high-content microscopy system (Cytiva). Nuclei counts were obtained with automated IN Carta Image Analysis Software (Cytiva) to determine the percentage of surviving cells compared to uninfected controls. *LRRC15* and control plasmid-transfected cells were normalized to the average cell count of uninfected wells for the corresponding cell type to determine the extent of normalized cell death.

Single cell RNA-sequencing analysis

LRRC15 expression was first queried on the COVID-19 cell atlas interactive website and summarized in Figure 5A. In depth analysis of lung single cell datasets were conducted on 3 studies (Bharat et al., 2020; Delorey et al., 2021; Melms et al., 2021) with Seurat V4.1.0 (Hao et al., 2021). Two single nucleus RNAseq datasets were downloaded from the Single Cell Portal (Broad Institute, SCP1052 and SCP1219) and one single cell RNAseq dataset from Gene Expression Omnibus (GSE158127). Their accompanying metadata, which includes information such as

sample ID, sample status and cluster annotations (cell types), were added to Seurat objects using the 'AddMetaData' function. Read counts were normalized using SCTransform, before reanalysis with the standard Seurat workflow of 'RunPCA,' 'FindNeighbours,' 'FindClusters,' and 'RunUMAP'. Cluster identities were assigned using published cluster annotations and plots were generated with 'DimPlot' and 'DotPlot'. The number of cells in each cluster from each study was then tabulated. 'Subset' was utilized to create new fibroblast only datasets before generating collagen (*COL1A1*, *COL1A2*, *COL8A1*, *COL11A1*, *COL12A1*) dotplots for *LRRC15*-expressing (*LRRC15*>0, Pos) and non-expressing (*LRRC15* = 0, Neg) fibroblasts.

Fibroblast infectivity and viral immobilization assay

LRRC15 expression in IMR90 lung fibroblasts were first compared with HEK293T cells by RT-qPCR. These cells were then transfected with empty *TurboGFP* control and *LRRC15-TurboGFP* (Lipofectamine LTX with plus reagent (ThermoScientific)). Cells were checked for Spike binding activity by incubation with Spike647 and detection via flow cytometry 24 h post-transduction. Then, these fibroblasts were infected with SARS-CoV-2 pseudovirus as described above and luciferase luminescence were compared to HEK293T-*ACE2-TMPRSS2* cells.

For viral immobilization assay, 6,000 HEK293T-*ACE2-TMPRSS2* cells were incubated with 12,000 fibroblasts expressing GFP or *LRRC15*-GFP and SARS-CoV-2 pseudovirus (5×10^8 particles in polybrene, as described above) for an hour at 37°C before seeding in a 96-well plate. Transduction was quantified as described above and luminescence was normalized to GFP controls.

Quantification of collagen production in fibroblast

5 ng/mL of TGF- β (R&D Systems) was added to fibroblasts and incubated for 24 h before collection for *LRRC15* and *COL1A1* RT-qPCR. For direct regulation experiments, a total of 1.25 μ g of plasmid DNA of either *LRRC15-TurboGFP* fusion construct (Origene, RG225990) or empty *TurboGFP* control plasmid were transfected into fibroblasts before treatment with spike and qPCR the following day. 1.25 μ g empty *TurboGFP* plasmid were transfected for 0 μ g LRRC15 cells, 0.3125 μ g *LRRC15* plasmid was mixed with 0.9375 μ g empty *TurboGFP* plasmid for Lo LRRC15 cell transfection and 1.25 μ g *LRRC15-TurboGFP* was transfected for Hi LRRC15 cells. Cells were collected at 72 h for *COL1A1* RT-qPCR and Western blots as described above (α -COL1A1,1:1000; α -ACTB,1:5000). Densitometry analysis of LRRC15, COL1A1 and ACTB were performed with ImageJ. Band intensities of LRRC15 and COL1A1 were normalized to ACTB.

Quantification and statistical analysis

SARS-CoV-2 spike glycoprotein titration experiments were analyzed on GraphPad Prism and fitted with non-linear regression (one site -- specific binding) to identify maximal binding (B_{max}) and dissociation constants (K_D). CRISPR activation screen analysis was performed using MAGeCK (v0.5.9) (Li et al., 2014). For each sample, Z-scores were calculated using normalized read counts. All density plots were generated using ggplot2. For SARS-CoV-2 pseudovirus and live virus experiments, data shown reflects 3 independent replicates. For pseudovirus, normalized level of transduction was calculated by dividing luminescence recorded for control and LRRC15-transfected cells by luminescence of non-transduced cells of the same cell line. Similarly, for live virus infection assays, cell death for both control and LRRC15-transfected cells was normalized

to uninfected controls. All RT-qPCR results were analyzed using $\Delta\Delta C_T$ method. For *COL1A1* RT-qPCR, *COL1A1* expression was normalised to 0 μ g LRRC15 cells. Significance for SARS-CoV-2 pseudotyped lentivirus and live virus experiments were analyzed with two-way ANOVA with Sidak Multiple Comparisons test. For inflammatory cytokine experiments, *LRRC15* RT-qPCR expression was analyzed with Mann-Whitney One-Tailed test normalized to control. Co-culture luminescence was analyzed with Mann-Whitney One-tailed test. *COL1A1* RT-qPCR expression in LRRC15 transfected fibroblasts were normalized to control cells and analyzed with Kruskal-Wallis with Dunn's Multiple Comparisons test. Western blot band intensity of COL1A1 and LRRC15 were normalized to ACTB and significance was determined by One-way ANOVA with Dunnett's Multiple Comparisons test.

Acknowledgements

We thank Novogene for CRISPRa library sequencing, Sydney Informatics Hub (Artemis HPC) for single cell data analysis infrastructure, Sydney Cytometry for flow cytometry and FACS support, the technical and scientific assistance of Sydney Microscopy & Microanalysis, the University of Sydney node of Microscopy Australia, Dr Megan Steain, Dr Mark Larance, Dr Sean Humphrey, Dr Gang Liu, Dr Phil Hansboro, Dr Tim Newsome and members of the Neely lab for helpful discussions. Figure illustrations were created with [BioRender.com](https://www.biorender.com).

Funding

G.N. is funded by the National Health and Medical Research Council (NHMRC) project grants APP1107514, APP1158164, APP1158165, the NSW Ministry of Health, and a philanthropic donation from Dr. John and Anne Chong. L.L. is funded by a Dr. John and Anne Chong Fellowship

for Genome Editing and seed funding from the Drug Discovery Initiative at the University of Sydney

Author contributions

LL, GGN conceived this project. LL, MW, AJC, AOS performed experiments. LL, MW, AJC, AOS, DH, GGN performed data analyses. FC facilitated the generation of CRISPRa clonal cell lines. CLM performed microscopy. MW, CED performed molecular cloning. AA generated ACE2 and ACE2-TMPRSS2 cell lines. ZH performed RT-qPCR. JKKL, KP, RS, JM produced Spike protein. LL, DH, ST, GGN provided supervision and project administration. LL, MW, DH, GGN wrote the manuscript with contributions from all authors.

Declaration of interests

The authors declare no competing interests.

Figure Legends

Figure 1 A sensitive FACS-based SARS-CoV-2 Spike binding assay amenable to high Throughput Screening

(A) Schematic of proposed SARS-CoV-2 Spike binding assay. HEK293T cells with stable integration of *ACE2* cDNA for overexpression (HEK293T-*ACE2*) are incubated with Alexa Fluor 488-conjugated SARS-CoV-2 Spike protein (Spike488). Spike488-binding cells are then detected by flow cytometry.

(B) Representative flow cytometry plots for *WT* HEK293T and HEK293T-*ACE2* incubated with Spike488. See also **Supplementary Figure 1B** for gating strategy.

(C) Titration of HEK293T-*ACE2* (*ACE2*) cells with *WT* HEK293T cells. 1% HEK293T-*ACE2* cells showed sufficient difference to baseline non-specific binding, a condition that likely mimics the real screen condition. Histogram summary showing mean fluorescence intensity (MFI) of flowed cells.

(D) Schematic of CRISPR activation (CRISPRa) system used. HEK293T cells express synergistic activation machinery (SAM), which includes VP64-dCas9-VP64 protein and helper proteins MS2, p65 and HSF. When transduced with single guide RNA (sgRNA) plasmids, the assembled CRISPRa complex uses MS2 stem loops to recruit the MS2-p65-HSF transcriptional activators. The sgRNA plasmid also encodes the PCP-p65-HSF complex which is recruited to PP7 aptamers in the sgRNA scaffold.

(E) Representative plot of flow cytometry analysis for a clonal HEK293T-CRISPRa cell line transduced with NTC sgRNA or *ACE2* sgRNA (expression confirmation via RT-qPCR in **Supplementary Figure 1A**).

Figure 2. Whole genome CRISPRa screening identified LRRC15 as a novel SARS-CoV-2 Spike-binding protein.

(A) Schematic of CRISPRa screen for identification of novel SARS-CoV-2 Spike-binding proteins. HEK293T-CRISPRa cells were transduced with a whole genome activation library at MOI = 0.5 and selected on puromycin. HEK293T-CRISPRa cells incubated with Spike488 were analyzed by FACS and genomic DNA extracted from both sorted cells and unsorted diversity control HEK293-CRISPRa cells. Genomic DNA underwent next generation sequencing for gene enrichment analysis.

(B) Ranking of all genes in screen 1 by $\log_2$ fold change calculated using MAGeCK and plotted using MAGeCKFlute. See also **Supplementary Table S1**

(C) Gene enrichment analysis of Screen 1 performed using MAGeCK. Horizontal dotted line indicates p-value = 0.05. Vertical dotted lines indicate $\log_2$ fold changes (LFCs) of -2 and 2. P-values and LFCs for all genes are reported in **Supplementary Table S1**. Plot generated using EnhancedVolcano (v1.10.0) R package.

(D) sgRNA Z-scores for screen 1 unsorted and sorted samples. Density curve for all sgRNA Z-scores in sample (i.e. sorted or unsorted) is shown in grey. Z-scores for ACE2 sgRNA are indicated by vertical blue lines. Z-scores for LRRC15 sgRNAs are indicated by vertical red lines.

(E) Flow cytometry analysis of HEK293T-CRISPRa cells transduced with three independent LRRC15 sgRNAs. HEK293T-*ACE2* (*ACE2* sgRNA3) cells were used as a positive control and NTC sgRNA-transduced HEK293T-CRISPRa cells were used as a negative control.

(F) Quantification of Spike647 binding in *ACE2* sgRNA3 and *LRRC15* sgRNA1 cells via flow cytometry. Dissociation constant (Kd) was calculated by fitting with non-linear regression (one site -- specific binding).

Figure 3 Confirmation of SARS-CoV-2 Spike and LRRC15 interaction

(A) LRRC15 contains 15 leucine-rich repeats, a short cytoplasmic C-terminus, and 2 glycosylation sites.

(B) Predicted protein structure of LRRC15.

(C) LRRC15 is part of the LRR-Tollkin family of proteins.

(D) Flow cytometry analysis of Alexa Fluor-647 (Spike647) binding in WT HEK293T cells, (E) HEK293T-*ACE2* and (F) HEK293T cells with stable expression of both *ACE2* cDNA and *TMPRSS2* cDNA (HEK293T-*ACE2-TMPRSS2*). Each cell line was transfected with plasmids encoding cDNA for GFP-tagged *LRRC15* (transcript 1 or 2) or with empty *GFP* vector as negative control plasmid.

(G) Histogram summary shows mean fluorescence intensity (MFI) of (D-F).

(H) Representative images of interaction between LRRC15-GFP and Alexa Fluor 647-conjugated SARS-CoV-2 HexaPro Spike protein in HEK293T cells. Images were taken at 40x magnification. Green = LRRC15-GFP, Red = Spike647, Blue = Hoechst-stained nuclei. Scale bar = 25 μ m.

(I) Immunoprecipitation of LRRC15 with Spike protein. Lysates of HEK293T cells transfected with GFP-tagged LRRC15 (transcript 1 or 2, LRRC15_1 and LRRC15_2, respectively) incubated with SARS-CoV-2 HexaPro Spike protein were immunoprecipitated using anti-LRRC15 primary antibody. Immunoblots were performed for LRRC15 and for SARS-CoV-2 HexaPro spike. I = input, FT = flow-through, E = elute.

Fig 4 LRRC15 suppresses SARS-CoV-2 infection.

(A) Luciferase assay for quantification of SARS-CoV-2 pseudovirus infection in (B) WT HEK293T (n=4) and (C) HEK293T-*ACE2-TMPRSS2* (n=3). Cells were transfected with plasmid encoding LRRC15 transcript 1 or empty vector as a control. Luminescence for *LRRC15* cells were normalized to Control cells. Significance was determined by two-way ANOVA, Sidak multiple comparison test; ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05.

(D) Cell death assay for quantification of D614G SARS-CoV-2 live virus infection in HEK293T-*ACE2-TMPRSS2* cells. Cell death was determined via nuclei counts 48 hours after addition of virus.

(E,F) Quantification of cell survival after incubation with (E) D614G (n=5) and (F) Delta (n=4) SARS-CoV-2 live virus. Significance was determined by two-way ANOVA, *p<0.05.

Figure 5 LRRC15 is expressed in lung fibroblasts and protects against virus infection.

(A) Overview of cell types expressing *LRRC15* from existing single cell RNA-sequencing datasets.

(B) UMAP plot of lung single nucleus RNAseq dataset (Melms et al).

(C) Feature plot and (D) Dotplot shows *LRRC15* is expressed in fibroblasts and neuronal cells.

Expression of *LRRC15* in fibroblasts is also observed in fibroblasts of separate studies (See

Supplementary Figure 5).

(E) Fibroblasts have intrinsic spike binding ability that can be further enhanced by LRRC15 overexpression. Fibroblasts were transfected with empty vector control or *LRRC15* cDNA, and spike binding capacity was quantified via flow cytometry. MFI = Mean Fluorescence Intensity.

(F) Fibroblasts do not have innate tropism for SARS-CoV-2 and overexpression of LRRC15 does not mediate infection. Untransfected, *GFP* and *LRRC15-GFP* transfected fibroblasts were transduced with 5×10^8 SARS-CoV-2 pseudovirus particles for 24 hours before quantification via luciferase assay. Transduction efficiency (luciferase luminescence) was compared to permissive cell line HEK293T-*ACE2-TMPRSS2*.

(G) LRRC15 expressing fibroblasts reduced SARS-CoV-2 pseudovirus transduction in HEK293T-*ACE2-TMPRSS2*. Luminescence of *LRRC15*⁺ co-culture was normalized to control *GFP* co-culture, and significance was determined by two-way ANOVA, Sidak's multiple comparison test **** $p < 0.0001$, *** $p < 0.001$, ** $p < 0.01$, * $p < 0.05$.

Figure 6 LRRC15 controls collagen production.

(A) Pooled analysis of 3 independent studies show increase in fibroblasts proportion in COVID lungs (7.9% in control (n=19) and 22.9% in COVID (n=47); Unpaired t test, $p < 0.0001$).

(B) *LRRC15*⁺ fibroblasts have an enhanced collagen gene signature. Dotplots generated from 3 separate studies. Pos = *LRRC15*⁺, Neg = *LRRC15*⁻.

(C,D) TGF β increased *LRRC15* and *COL1A1* in fibroblasts. Quantification of *LRRC15* (C) and *COL1A1* (D) expression via RT-qPCR. Significance was determined by Mann-Whitney One-Tailed test, ** $p < 0.01$.

(E,F) LRRC15 regulates *COL1A1* expression. Quantification of *LRRC15* (E) and *COL1A1* (F) expression in *GFP* control, *Lo LRRC15-GFP* and *Hi LRRC-GFP* fibroblasts via RT-qPCR. *Lo LRRC15* increased *COL1A1* expression. Significance was determined by Kruskal-Wallis with Dunn's Multiple Comparisons test, compared to control GFP, * $p < 0.05$.

(G-I) Bimodal regulation was also confirmed at the protein level. Representative images of Western blots of LRRC15 and COL1A1 (F, full blots in Supplementary Figure 6). Intensity of LRRC15 and COL1A1 bands were normalized to their respective β -ACTIN bands. Significance was determined by One-way ANOVA with Dunnett's Multiple Comparisons test, compared to control GFP, **p<0.01.

(J) Summary schematic of LRRC15's role in COVID. Inflammation increase LRRC15 to immobilize SARS-CoV-2 and regulate collagen production.

Supplementary Figure 1. CRISPR activation screen setup.

(A) RT-qPCR of ACE2 expression in 3 SAM clonal cell lines transduced with 3 sgRNAs that increase expression of ACE2, and with HEK293T-ACE2 cells. Results calculated using $-\Delta\Delta C_T$ method and normalized to non-targeting control (NTC) sgRNA-transduced HEK293T-CRISPRa cells.

(B) FACS gating strategy. Cells were first gated by forward (FSC) and side scatter (SSC) before filtering for singlets. Spike fluorescence was gated by comparison with non-targeting sgRNA transduced cells. Similar strategy was applied to all flow cytometry experiments.

(C) FACS results for 3 whole genome CRISPRa screens with NTC as negative controls. For screen 1, cells were incubated with Alexa Fluor 488-conjugated SARS-CoV-2 HexaPro Spike (Addgene #154754) and selected on puromycin for 3 days. For screen 2, cells were incubated with Alexa Fluor 488-conjugated SARS-CoV-2 Spike glycoprotein (residues 1-1208, complete ectodomain; gift from Dr. Florian Krammer) and selected on puromycin for 3 days. For screen 3, cells were incubated with Alexa Fluor 488-conjugated SARS-CoV-2 HexaPro spike (Addgene #15474) and selected on puromycin for 8 days.

878

879 **Supplementary Figure 2. CRISPR screen analysis and validation.**

880 (A-B) Gene enrichment analysis of screens 2 (A) and 3 (B) performed using MAGeCK. Horizontal
881 dotted line indicates p -value = 0.05. Vertical dotted lines indicate $\log_2$ fold changes (LFCs) of -2
882 and 2. P -values and LFCs for all genes in screens 2 and 3 are reported in **Supplementary Table**
883 **S1**. Plots were generated using EnhancedVolcano (v1.10.0) R package.

884 (C-D) Density plot of Z-score (grey) for all sgRNA in (C) screen 2 and (D) screen 3. Blue vertical
885 lines indicate Z-score for *ACE2* sgRNAs. Red vertical lines indicate Z-score for *LRRC15* sgRNAs.
886 Z-scores calculated as described in methods.

887 (E) $\log_2$ fold changes of all genes in Screen 1 vs. $\log_2$ fold changes of all genes in Screen 2.

888 (F) $\log_2$ fold changes of all genes in Screen 1 vs. $\log_2$ fold changes of all genes in Screen 3.

889 (G) *LRRC15* expression of cells in Fig 2E quantified via RT-qPCR.

890 (H) *ACE2* expression was not increased in *LRRC15* sgRNA transduced cells (quantified via RT-
891 qPCR).

892 (I) The 3 sgRNAs for *ACE2* from the Calabrese library used in our screens were transduced into
893 HEK293T-CRISPRa cells and *ACE2* expression was confirmed via qPCR. Only sgRNA3 induced
894 upregulation in *ACE2* expression.

895 (J) Transduced cells in (I) were incubated with Spike647 and analyzed via flow cytometry. Only
896 *ACE2* sgRNA3 cells showed a significant increase in Spike647 binding.

897

898 **Supplementary Fig 3. LRRC15 is related to TLRs and interacts with Spike.**

899 (A) Full phylogenetic tree of LRR-Tollkin family of proteins (includes fly and worm orthologs).

(B) Co-immunoprecipitation of Spike was observed in LRRC15-GFP (transcripts 1 and 2) and ACE2 expressing cells but not in control GFP WT cells. I = input, FT = flow-through, E = elute.

(C) Control rabbit IgG did not immunoprecipitate LRRC15 or Spike.

Supplementary Fig 4. LRRC15 expression inhibits SARS-CoV-2 spike pseudovirus infection in ACE2 expression cells.

(A) SARS-CoV-2 pseudovirus carrying a firefly luciferase cassette was applied to HEK293T, HEK293T-*ACE2* and HEK293T-*ACE2-TMPRSS2* cells for 24 hours before luminescence quantification. HEK293T cells were relatively resistant to infection while HEK293T-*ACE2* and HEK293T-*ACE2-TMPRSS2* expressing cells were infectable.

(B) Pseudovirus added to ACE2-expressing cells in the context of LRRC15. Titration of 15×10^6 , 62.5×10^6 , 250×10^6 and 1000×10^6 lentiviral particles in HEK293T-ACE2 cells transfected with 0, 156.25, 312.5, 625, 1250 and 2500 ng of *LRRC15* plasmid DNA.

(C) Normalized *LRRC15*-mediated inhibition in HEK293T-*ACE2* cells.

Supplementary Fig 5. Single cell/nucleus analysis of different studies corroborates restricted LRRC15 expression in fibroblasts.

(A) UMAP plot of lung single nucleus RNAseq dataset (Delorey et al).

(B) Feature plot and (C) Dotplot shows *LRRC15* is expressed in Delorey et al. fibroblasts.

(D) UMAP plot of lung single nucleus RNAseq dataset (Bharat et al).

(E) Feature plot and (F) Dotplot shows *LRRC15* is expressed in Bharat et al. Lymphatic Endothelial cells and various populations of fibroblasts.

(G) IMR90 fibroblasts express *LRRC15*, quantified via RT-qPCR.

923 (H) These fibroblasts have intrinsic spike binding activity.

924 (I) Fibroblasts do not have intrinsic tropism and LRRC15 is not an entry receptor for SARS-CoV-
925 2 pseudovirus.

926

927 **Supplementary Fig 6. Bimodal regulation of COL1A1 by LRRC15.**

928 (A) Full western blots of LRRC15 and COL1A1 of 3 replicates.

929 (B) Densitometry analysis of endogenous LRRC1, normalized to β -ACTIN.

930

931 **Supplementary Table 1: CRISPR activation screen MAGeCK outputs.**

932 Collated output of MAGeCK and MAGeCKFlute pipeline. For each screen, normalized read
933 counts and Z-scores, gene-level summary, sgRNA-level summary and output of MAGeCKFlute
934 ReadRRA() function is provided.

935

936 **Supplementary Table 2: Oligonucleotides for CRISPR activation sgRNA constructs**

937 Lists oligonucleotides used for generation of CRISPRa sgRNA constructs. Sequences for each
938 sgRNA construct were from either Weismann lab Human Genome-wide CRISPRa-v2 Library
939 (Addgene, #83978) or Calabrese Library Set A (Addgene, #92379).

940

941 **Supplementary Table 3: Next Generation Sequencing Primers**

942 List of primers used for next generation sequencing of gDNA extracted from pooled CRISPR
943 activation screen samples. Primers were adapted from adapted from Sanson et al. (Sanson et al.,
944 2018)

945

946 **Supplementary Table 4: RT-qPCR primer sequences**

947 List of primers used for RT-qPCR.

948

949

950

951 **Key Resources Table (KRT)**

952

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
ACE2 Recombinant Rabbit Monoclonal Antibody (SN0754)	ThermoFisher Scientific	MA5-32307 RRID:AB_2809589
beta Actin antibody [AC-15]	Abcam	ab6276-50ul RRID:AB_2223210
Collagen Type I Polyclonal antibody	Proteintech Group	14695-1-AP RRID:AB_2082037
IRDye® 680RD Goat anti-Mouse IgG Secondary Antibody	Li-Cor Biosciences	926-68070 RRID AB_2651128
IRDye® 800CW Goat anti-Rabbit IgG Secondary Antibody	Li-Cor Biosciences	925-32211 RRID AB_2651127
Purified Rabbit Polyclonal Isotype Ctrl Antibody	Covance	CTL-4112 RRID:AB_2722735
Recombinant Anti-LRRC15 antibody [EPR8188(2)] (ab150376)	Abcam	ab150376-100ul
SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9]	GeneTex	GTX632604 RRID:AB_2864418
Bacterial and virus strains		

DH10B Electrocompetent E. coli	Life Technologies Australia	C640003
NEB® 10-beta Competent E. coli (High Efficiency)	New England Biolabs	C3019I
SARS-CoV-2 B.1.319 (D614G genotype)	Turville lab	NA
SARS-CoV-2 B.1.617.2 (Delta strain)	Turville lab	NA
Chemicals, peptides, and recombinant proteins		
Ampicillin sodium salt	Sigma-Aldrich	A9518
BamHI-HF	New England Biolabs	R3136S
Blasticidin S Hydrochloride	Merck	US1203350-25MG
Bovine Serum Albumin	Sigma-Aldrich	A9647
BsmBI-v2	New England Biolabs	R0739L
Carbenicillin	Merck	US169101-3
Dulbecco's Modified Eagle Medium	ThermoFisher Scientific	11995065
Dulbecco's Phosphate Buffered Saline	Sigma-Aldrich	D8537
Dynabeads™ Protein G for Immunoprecipitation	ThermoFisher Scientific	10003D
EDTA-free Protease Inhibitor Cocktail	Roche	11873580001
Esp3I	New England Biolabs	R0734L
Human LRRC15 Protein (ECD, Fc Tag)	Sino Biological	15786-H02H

HyClone Characterized Fetal Bovine Serum, AU Origin	Cytiva	SH30084.03
Igepal-CA-630	Sigma-Aldrich	I8896
Intercept (TBS) Blocking Buffer	LI-COR	927-60001
iScript Select cDNA Synthesis Kit	Bio-Rad	1708841
LB Agar, powder (Lennox L agar)	Life Technologies	22700025
Lipofectamine 3000 Transfection Reagent	ThermoFisher Scientific	L3000075
Lipofectamine™ LTX with Plus™ Reagent	ThermoFisher Scientific	15338100
Luria Broth Base (Miller's LB Broth Base)	Life Technologies	12795084
Matrigel Matrix hESC-Qualified	Corning	354277
MluI	New England Biolabs	R0198S
NEBNext High Fidelity 2X PCR Master Mix	New England Biolabs	M0541L
Ni-NTA agarose	ThermoFisher Scientific	R90115
Non-essential amino acids	Gibco	11140050
NucBlue Live Ready Probes (Hoechst 33342)	Invitrogen	R37605
Opti-MEM I Reduced Serum Medium	Gibco	31985070
Polyethylenimine, Linear, MW 25000, Transfection Grade (PEI 25K™)	Polysciences Inc.	23966
Penicillin-Streptomycin	Gibco	15140122
Polybrene Infection / Transfection Reagent	Sigma-Aldrich	TR-1003

Puromycin dihydrochloride	Gibco	A1113803
Recombinant Human TGF-beta 1 Protein	R&D Systems	240-B-002/CF
SYBR Select Master Mix	ThermoFisher Scientific	4472908
T4 ligase	New England Biolabs	M0202L
TrypLE Express enzyme (1X), phenol red	Life Technologies	12605028
Critical commercial assays		
Agilent High Sensitivity DNA Kit (Chips and Reagents) For 110 samples	Agilent	5067-4626
Alexa Fluor™ 488 protein labelling kit	Invitrogen	A10235
Alexa Fluor™ 647 protein labelling kit	Invitrogen	A20173
Bicinchoninic acid assay	ThermoFisher Scientific	23225
ISOLATE II Genomic DNA Kit	Bioline	BIO-52067
ISOLATE II PCR & Gel Kit	Bioline	BIO-52060
ISOLATE II Plasmid Mini Kit	Bioline	BIO-52067
ISOLATE II RNA Mini Kit	Bioline	BIO-52072
PureYield Plasmid Maxiprep System	Promega Corporation	A2393
QuickTiter™ Lentivirus Titer Kit (Lentivirus-Associated HIV p24)	Cell Biolabs, Inc	VPK-107
Steady-Glo Luciferase Assay System	Promega Corporation	E2520

Deposited data		
CRISPR activation screen next-generation sequencing fastq files and processed read counts from MAGeCK	This paper	GSE186475
Lung transplantation for patients with severe COVID-19	(Bharat et al., 2020)	GSE158127
Single nucleus and single cell transcriptomic analysis of COVID-19 lung samples	(Delorey et al., 2021)	SCP1052
A molecular single-cell lung atlas of lethal COVID-19	(Melms et al., 2021)	SCP1219
Experimental models: Cell lines		
Expi293F™ Cells	ThermoFisher Scientific	A14527 RRID:CVCL_D615
HEK293T	ATCC	CRL-3216 RRID: CVCL_0063
HEK293T-ACE2	(Tea et al., 2021)	NA
HEK293T-ACE2-TMPRSS2	(Tea et al., 2021)	NA
IMR90 E6E7	(Cesare et al., 2013)	NA
Oligonucleotides		
Oligonucleotides for CRISPR activation sgRNA constructs, see Supplementary Table S2	This study	NA
Next Generation Sequencing Primers, see Supplementary Table S3	Adapted from Sanson et al. (Sanson et al., 2018)	NA

RT-qPCR primers, see Supplementary Table S4	This study	NA
Recombinant DNA		
Human CRISPR Activation Pooled Library (Calabrese P65-HSF)	(Sanson et al., 2018)	Addgene #92379 RRID:Addgene_92379
LRRC15 (GFP-tagged) - Human leucine rich repeat containing 15 (LRRC15), transcript variant 1	Origene Technologies	RG225990
LRRC15 (GFP-tagged) - Human leucine rich repeat containing 15 (LRRC15), transcript variant 2	Origene Technologies	RG221437
LRRC15 (myc-DDK-tagged)-Human leucine rich repeat containing 15 (LRRC15), transcript variant 1	Origene Technologies	RC225990
LRRC15 (myc-DDK-tagged)-Human leucine rich repeat containing 15 (LRRC15), transcript variant 2	Origene Technologies	RC221437
pBCKS(HIV-1SDmCMBEGFP-P2A-luc2pre-IIU)	(Koldej et al., 2005)	NA
pCAG-VSVg	Arthur Nienhuis & Patrick Salmon	Addgene #35616 RRID:Addgene_35616
pcDNA3.1tat101ml	(Koldej et al., 2005)	NA
pHCMVgagpolmlstwhv	(Koldej et al., 2005)	NA
pHCMVRevmlwhvpre	(Koldej et al., 2005)	NA
pLJM1-EGFP	(Sancak et al., 2008)	Addgene #19319 RRID:Addgene_19319
pLVX-IRES-ZsGreen1	Clontech	632187

pMD2.G	Trono Lab Packaging and Envelope Plasmids	Addgene #12259 RRID:Addgene_12259
pPB- R1R2_EF1aVP64dCas9VP64_T2A_MS2p65HSF1- IRESbsdpa	(Chong et al., 2018)	Addgene #113341 RRID:Addgene_113341
pRRLsinPPT.CMV.GFP.WPRE	Trono Lab Misc Plasmids	Addgene #12252 RRID:Addgene_12252
pSARS-CoV-2 Spike_018aa_Lenti	(Hoffmann et al., 2020)	NA
psPAX2	Trono Lab Packaging and Envelope Plasmids	Addgene #12260 RRID:Addgene_12260
pXPR_502	(Sanson et al., 2018)	Addgene #96923 RRID:Addgene_96923
SARS-CoV-2 S HexaPro	(Hsieh et al., 2020)	Addgene #154754 RRID:Addgene_154754
SARS-CoV-2 spike protein (residues 1-1208, complete ectodomain)	Gift from Dr. Florian Krammer	NA
Super PiggyBac Transposase Expression Vector	System Biosciences	PB210PA-1
Software and algorithms		
AlphaFold v2.0	(Jumper et al., 2021)	https://alphafold.ebi.ac. uk/
Clustal Omega v1.2.2	(Sievers et al., 2011)	http://www.clustal.org/

EnhancedVolcano v1.10.0	(Blighe, 2018)	https://bioconductor.org/packages/EnhancedVolcano/
FlowJo	FlowJo	https://www.flowjo.com/solutions/flowjo/downloads
GraphPad Prism 9	GraphPad Software	https://www.graphpad.com/scientific-software/prism/
Image Studio	LI-COR	https://www.licor.com/bio/image-studio/
IN Carta Image Analysis Software	Cytiva	https://www.moleculardevices.com/products/cellular-imaging-systems/acquisition-and-analysis-software/in-carta-image-analysis-software
MAGeCKFlute v1.12.0	(Wang et al., 2019)	https://www.bioconductor.org/packages/release/bioc/html/MAGeCKFlute.html
MEGA11	(Stecher et al., 2020)	http://www.megasoftware.net/

Model-based Analysis of Genome-wide CRISPR/Cas9 Knockout (MAGeCK; v0.5.9)	(Li et al., 2014)	https://sourceforge.net/ projects/mageck/
Seurat v4.1.0	(Hao et al., 2021)	https://satijalab.org/seur at/
Other		
100K MWCO Pierce Protein Concentrators	Life Technologies Australia	88533
4–20% Mini-PROTEAN® TGX™ Precast Protein Gels, 15-well, 15 µl	Bio-rad	4561096
Fisherbrand™ Superfrost™ Plus Microscope Slides	Fisherbrand	22-037-246
HiLoad® 16/600 Superdex® 200 pg	Cytiva	GE28-9893-35
Superdex® 200 10/300 GL	Cytiva	GE17-5175-01

References

Aggarwal, A., Iemma, T.L., Shih, I., Newsome, T.P., McAllery, S., Cunningham, A.L., and
Turville, S.G. (2012). Mobilization of HIV spread by diaphanous 2 dependent filopodia in
infected dendritic cells. PLoS Pathog. 8, e1002762.

962 Baggen, J., Persoons, L., Vanstreels, E., Jansen, S., Van Looveren, D., Boeckx, B., Geudens, V.,
963 De Man, J., Jochmans, D., Wauters, J., et al. (2021). Genome-wide CRISPR screening identifies
964 TMEM106B as a proviral host factor for SARS-CoV-2. *Nat. Genet.* 53, 435–444.

965 Bharat, A., Querrey, M., Markov, N.S., Kim, S., Kurihara, C., Garza-Castillon, R., Manerikar,
966 A., Shilatifard, A., Tomic, R., Politanska, Y., et al. (2020). Lung transplantation for patients with
967 severe COVID-19. *Sci. Transl. Med.* 12.

968 Blighe, K. (2018). EnhancedVolcano (Bioconductor).

969 Buechler, M.B., Pradhan, R.N., Krishnamurty, A.T., Cox, C., Calviello, A.K., Wang, A.W.,
970 Yang, Y.A., Tam, L., Caothien, R., Roose-Girma, M., et al. (2021). Cross-tissue organization of
971 the fibroblast lineage. *Nature* 593, 575–579.

972 Cesare, A.J., Hayashi, M.T., Crabbe, L., and Karlseder, J. (2013). The telomere deprotection
973 response is functionally distinct from the genomic DNA damage response. *Mol. Cell* 51, 141–
974 155.

975 Chong, Z.-S., Ohnishi, S., Yusa, K., and Wright, G.J. (2018). Pooled extracellular receptor-
976 ligand interaction screening using CRISPR activation. *Genome Biol.* 19, 205.

977 Daniloski, Z., Jordan, T.X., Wessels, H.-H., Hoagland, D.A., Kasela, S., Legut, M., Maniatis, S.,
978 Mimitou, E.P., Lu, L., Geller, E., et al. (2021). Identification of Required Host Factors for
979 SARS-CoV-2 Infection in Human Cells. *Cell* 184, 92–105.e16.

980 Delorey, T.M., Ziegler, C.G.K., Heimberg, G., Normand, R., Yang, Y., Segerstolpe, Å.,
981 Abbondanza, D., Fleming, S.J., Subramanian, A., Montoro, D.T., et al. (2021). COVID-19 tissue

982 atlases reveal SARS-CoV-2 pathology and cellular targets. *Nature* 595, 107–113.

983 Dolan, J., Walshe, K., Alsbury, S., Hokamp, K., O’Keeffe, S., Okafuji, T., Miller, S.F.C., Tear,
984 G., and Mitchell, K.J. (2007). The extracellular leucine-rich repeat superfamily; a comparative
985 survey and analysis of evolutionary relationships and expression patterns. *BMC Genomics* 8,
986 320.

987 Follenzi, A., Battaglia, M., Lombardo, A., Annoni, A., Roncarolo, M.G., and Naldini, L. (2004).
988 Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response
989 and establishes long-term expression of human antihemophilic factor IX in mice. *Blood* 103,
990 3700–3709.

991 George, P.M., Wells, A.U., and Jenkins, R.G. (2020). Pulmonary fibrosis and COVID-19: the
992 potential role for antifibrotic therapy. *Lancet Respir Med* 8, 807–815.

993 Goujon, C., Rebendenne, A., Roy, P., Bonaventure, B., Valadao, A.C., Desmarests, L., Rouillé,
994 Y., Tauziet, M., Arnaud-Arnould, M., Giovannini, D., et al. (2021). Bidirectional genome-wide
995 CRISPR screens reveal host factors regulating SARS-CoV-2, MERS-CoV and seasonal HCoVs.
996 *Res Sq.*

997 Hao, Y., Hao, S., Andersen-Nissen, E., Mauck, W.M., 3rd, Zheng, S., Butler, A., Lee, M.J.,
998 Wilk, A.J., Darby, C., Zager, M., et al. (2021). Integrated analysis of multimodal single-cell data.
999 *Cell* 184, 3573–3587.e29.

1000 Hayashi, F., Smith, K.D., Ozinsky, A., Hawn, T.R., Yi, E.C., Goodlett, D.R., Eng, J.K., Akira,
1001 S., Underhill, D.M., and Aderem, A. (2001). The innate immune response to bacterial flagellin is
1002 mediated by Toll-like receptor 5. *Nature* 410, 1099–1103.

1003 Henry, G.H., Malewska, A., Joseph, D.B., Malladi, V.S., Lee, J., Torrealba, J., Mauck, R.J.,
 1004 Gahan, J.C., Raj, G.V., Roehrborn, C.G., et al. (2018). A Cellular Anatomy of the Normal Adult
 1005 Human Prostate and Prostatic Urethra. *Cell Rep.* 25, 3530–3542.e5.
 1006 Hoffmann, M., Kleine-Weber, H., and Pöhlmann, S. (2020). A Multibasic Cleavage Site in the
 1007 Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. *Mol. Cell* 78,
 1008 779–784.e5.
 1009 Horlbeck, M.A., Gilbert, L.A., Villalta, J.E., Adamson, B., Pak, R.A., Chen, Y., Fields, A.P.,
 1010 Park, C.Y., Corn, J.E., Kampmann, M., et al. (2016). Compact and highly active next-generation
 1011 libraries for CRISPR-mediated gene repression and activation. *Elife* 5.
 1012 Hsieh, C.-L., Goldsmith, J.A., Schaub, J.M., DiVenere, A.M., Kuo, H.-C., Javanmardi, K., Le,
 1013 K.C., Wrapp, D., Lee, A.G., Liu, Y., et al. (2020). Structure-based design of prefusion-stabilized
 1014 SARS-CoV-2 spikes. *Science* 369, 1501–1505.
 1015 Huang, N., Pérez, P., Kato, T., Mikami, Y., Okuda, K., Gilmore, R.C., Conde, C.D., Gasmi, B.,
 1016 Stein, S., Beach, M., et al. (2021). SARS-CoV-2 infection of the oral cavity and saliva. *Nat.*
 1017 *Med.* 27, 892–903.
 1018 Jia, H.P., Look, D.C., Shi, L., Hickey, M., Pewe, L., Netland, J., Farzan, M., Wohlford-Lenane,
 1019 C., Perlman, S., and McCray, P.B., Jr (2005). ACE2 receptor expression and severe acute
 1020 respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia.
 1021 *J. Virol.* 79, 14614–14621.
 1022 Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool,
 1023 K., Bates, R., Židek, A., Potapenko, A., et al. (2021). Highly accurate protein structure prediction

1024 with AlphaFold. *Nature* 596, 583–589.

1025 Koldej, R., Cmielewski, P., Stocker, A., Parsons, D.W., and Anson, D.S. (2005). Optimisation of
1026 a multipartite human immunodeficiency virus based vector system; control of virus infectivity
1027 and large-scale production. *J. Gene Med.* 7, 1390–1399.

1028 Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., Huan, Y., Yang, P., Zhang, Y., Deng,
1029 W., et al. (2005). A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS
1030 coronavirus-induced lung injury. *Nat. Med.* 11, 875–879.

1031 Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al.
1032 (2020). Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2
1033 receptor. *Nature* 581, 215–220.

1034 Li, W., Moore, M.J., Vasilieva, N., Sui, J., Wong, S.K., Berne, M.A., Somasundaran, M.,
1035 Sullivan, J.L., Luzuriaga, K., Greenough, T.C., et al. (2003). Angiotensin-converting enzyme 2 is
1036 a functional receptor for the SARS coronavirus. *Nature* 426, 450–454.

1037 Li, W., Xu, H., Xiao, T., Cong, L., Love, M.I., Zhang, F., Irizarry, R.A., Liu, J.S., Brown, M.,
1038 and Liu, X.S. (2014). MAGeCK enables robust identification of essential genes from genome-
1039 scale CRISPR/Cas9 knockout screens. *Genome Biol.* 15, 554.

1040 Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et
1041 al. (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: implications
1042 for virus origins and receptor binding. *Lancet* 395, 565–574.

1043 Madissoon, E., Wilbrey-Clark, A., Miragaia, R.J., Saeb-Parsy, K., Mahbubani, K.T.,

1044 Georgakopoulos, N., Harding, P., Polanski, K., Huang, N., Nowicki-Osuch, K., et al. (2019).
 1045 scRNA-seq assessment of the human lung, spleen, and esophagus tissue stability after cold
 1046 preservation. *Genome Biol.* *21*, 1.

1047 Martin, J.C., Chang, C., Boschetti, G., Ungaro, R., Giri, M., Grout, J.A., Gettler, K., Chuang, L.-
 1048 S., Nayar, S., Greenstein, A.J., et al. (2019). Single-Cell Analysis of Crohn's Disease Lesions
 1049 Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy. *Cell*
 1050 *178*, 1493–1508.e20.

1051 Melms, J.C., Biermann, J., Huang, H., Wang, Y., Nair, A., Tagore, S., Katsyv, I., Rendeiro, A.F.,
 1052 Amin, A.D., Schapiro, D., et al. (2021). A molecular single-cell lung atlas of lethal COVID-19.
 1053 *Nature* *595*, 114–119.

1054 Neil, S.J.D., Zang, T., and Bieniasz, P.D. (2008). Tetherin inhibits retrovirus release and is
 1055 antagonized by HIV-1 Vpu. *Nature* *451*, 425–430.

1056 O'Prey, J., Wilkinson, S., and Ryan, K.M. (2008). Tumor antigen LRRC15 impedes adenoviral
 1057 infection: implications for virus-based cancer therapy. *J. Virol.* *82*, 5933–5939.

1058 Park, J.-E., Botting, R.A., Domínguez Conde, C., Popescu, D.-M., Lavaert, M., Kunz, D.J., Goh,
 1059 I., Stephenson, E., Ragazzini, R., Tuck, E., et al. (2020). A cell atlas of human thymic
 1060 development defines T cell repertoire formation. *Science* *367*.

1061 Rendeiro, A.F., Ravichandran, H., Bram, Y., Chandar, V., Kim, J., Meydan, C., Park, J., Foox,
 1062 J., Hether, T., Warren, S., et al. (2021). The spatial landscape of lung pathology during COVID-
 1063 19 progression. *Nature* *593*, 564–569.

1064 Sancak, Y., Peterson, T.R., Shaul, Y.D., Lindquist, R.A., Thoreen, C.C., Bar-Peled, L., and
1065 Sabatini, D.M. (2008). The Rag GTPases bind raptor and mediate amino acid signaling to
1066 mTORC1. *Science* 320, 1496–1501.

1067 Sanson, K.R., Hanna, R.E., Hegde, M., Donovan, K.F., Strand, C., Sullender, M.E., Vaimberg,
1068 E.W., Goodale, A., Root, D.E., Piccioni, F., et al. (2018). Optimized libraries for CRISPR-Cas9
1069 genetic screens with multiple modalities. *Nat. Commun.* 9, 5416.

1070 Satoh, K., Hata, M., and Yokota, H. (2002). A novel member of the leucine-rich repeat
1071 superfamily induced in rat astrocytes by beta-amyloid. *Biochem. Biophys. Res. Commun.* 290,
1072 756–762.

1073 Schneider, W.M., Luna, J.M., Hoffmann, H.-H., Sánchez-Rivera, F.J., Leal, A.A., Ashbrook,
1074 A.W., Le Pen, J., Ricardo-Lax, I., Michailidis, E., Peace, A., et al. (2021). Genome-Scale
1075 Identification of SARS-CoV-2 and Pan-coronavirus Host Factor Networks. *Cell* 184, 120–
1076 132.e14.

1077 Shilts, J., Crozier, T.W.M., Teixeira-Silva, A., Gabaev, I., Greenwood, E.J.D., Watson, S.J.,
1078 Ortmann, B.M., Gawden-Bone, C.M., Pauzaite, T., Hoffmann, M., et al. (2021). LRRRC15
1079 mediates an accessory interaction with the SARS-CoV-2 spike protein. *bioRxiv*
1080 2021.09.25.461776; doi: <https://doi.org/10.1101/2021.09.25.461776>.

1081 Sievers, F., Wilm, A., Dineen, D., Gibson, T.J., Karplus, K., Li, W., Lopez, R., McWilliam, H.,
1082 Remmert, M., Söding, J., et al. (2011). Fast, scalable generation of high-quality protein multiple
1083 sequence alignments using Clustal Omega. *Mol. Syst. Biol.* 7, 539.

1084 Spandidos, A., Wang, X., Wang, H., and Seed, B. (2010). PrimerBank: a resource of human and

1085 mouse PCR primer pairs for gene expression detection and quantification. *Nucleic Acids Res.*
 1086 *38*, D792–D799.

1087 Solé-Boldo, L., Raddatz, G., Schütz, S., Mallm, J.-P., Rippe, K., Lonsdorf, A.S., Rodríguez-
 1088 Paredes, M., and Lyko, F. (2020). Single-cell transcriptomes of the human skin reveal age-
 1089 related loss of fibroblast priming. *Commun Biol* *3*, 188.

1090 Stecher, G., Tamura, K., and Kumar, S. (2020). Molecular Evolutionary Genetics Analysis
 1091 (MEGA) for macOS. *Mol. Biol. Evol.* *37*, 1237–1239.

1092 Tea, F., Ospina Stella, A., Aggarwal, A., Ross Darley, D., Pilli, D., Vitale, D., Merheb, V., Lee,
 1093 F.X.Z., Cunningham, P., Walker, G.J., et al. (2021). SARS-CoV-2 neutralizing antibodies:
 1094 Longevity, breadth, and evasion by emerging viral variants. *PLoS Med.* *18*, e1003656.

1095 Uhlén, M., Fagerberg, L., Hallström, B.M., Lindskog, C., Oksvold, P., Mardinoglu, A.,
 1096 Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015). Proteomics. Tissue-based map
 1097 of the human proteome. *Science* *347*, 1260419.

1098 UniProt Consortium (2021). UniProt: the universal protein knowledgebase in 2021. *Nucleic*
 1099 *Acids Res.* *49*, D480–D489.

1100 Vento-Tormo, R., Efremova, M., Botting, R.A., Turco, M.Y., Vento-Tormo, M., Meyer, K.B.,
 1101 Park, J.-E., Stephenson, E., Polański, K., Goncalves, A., et al. (2018). Single-cell reconstruction
 1102 of the early maternal-fetal interface in humans. *Nature* *563*, 347–353.

1103 Vieira Braga, F.A., Kar, G., Berg, M., Carpaij, O.A., Polanski, K., Simon, L.M., Brouwer, S.,
 1104 Gomes, T., Hesse, L., Jiang, J., et al. (2019). A cellular census of human lungs identifies novel

1105 cell states in health and in asthma. *Nat. Med.* 25, 1153–1163.

1106 Wang, B., Wang, M., Zhang, W., Xiao, T., Chen, C.-H., Wu, A., Wu, F., Traugh, N., Wang, X.,
 1107 Li, Z., et al. (2019). Integrative analysis of pooled CRISPR genetic screens using
 1108 MAGeCKFlute. *Nat. Protoc.* 14, 756–780.

1109 Wang, Q., Zhang, Y., Wu, L., Niu, S., Song, C., Zhang, Z., Lu, G., Qiao, C., Hu, Y., Yuen, K.-
 1110 Y., et al. (2020). Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2.
 1111 *Cell* 181, 894–904.e9.

1112 Wang, R., Simoneau, C.R., Kulsuptrakul, J., Bouhaddou, M., Travisano, K.A., Hayashi, J.M.,
 1113 Carlson-Stevermer, J., Zengel, J.R., Richards, C.M., Fozouni, P., et al. (2021). Genetic Screens
 1114 Identify Host Factors for SARS-CoV-2 and Common Cold Coronaviruses. *Cell* 184, 106–
 1115 119.e14.

1116 Wang, Y., Liu, Y., Zhang, M., Lv, L., Zhang, X., Zhang, P., and Zhou, Y. (2018). LRRC15
 1117 promotes osteogenic differentiation of mesenchymal stem cells by modulating p65
 1118 cytoplasmic/nuclear translocation. *Stem Cell Res. Ther.* 9, 65.

1119 Wei, J., Alfajaro, M.M., DeWeirdt, P.C., Hanna, R.E., Lu-Culligan, W.J., Cai, W.L., Strine,
 1120 M.S., Zhang, S.-M., Graziano, V.R., Schmitz, C.O., et al. (2021). Genome-wide CRISPR
 1121 Screens Reveal Host Factors Critical for SARS-CoV-2 Infection. *Cell* 184, 76–91.e13.

1122 Wrapp, D., Wang, N., Corbett, K.S., Goldsmith, J.A., Hsieh, C.-L., Abiona, O., Graham, B.S.,
 1123 and McLellan, J.S. (2020). Cryo-EM structure of the 2019-nCoV spike in the prefusion
 1124 conformation. *Science* 367, 1260–1263.

1125 Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B.,
1126 Huang, C.-L., et al. (2020). A pneumonia outbreak associated with a new coronavirus of
1127 probable bat origin. *Nature* 579, 270–273.

1128 Zhu, S., Liu, Y., Zhou, Z., Zhang, Z., Xiao, X., Liu, Z., Chen, A., Dong, X., Tian, F., Chen, S., et
1129 al. (2021). Genome-wide CRISPR activation screen identifies candidate receptors for SARS-
1130 CoV-2 entry. *Sci. China Life Sci.*

1131

1132

1133

1134

1135

1136

1137

Figure 1

Figure 2

Figure 3

Figure 4

Figure 6

Supplementary Figure 5

A **B**